EWTX NASDAQ
Edgewise Therapeutics, Inc.
1W: +3.3%
1M: -0.4%
3M: -2.9%
YTD: +64.9%
1Y: +159.4%
3Y: +432.2%
5Y: +125.5%
$39.53
+0.36 (+0.92%)
After Hours: $38.52 (-1.01, -2.54%)
Weekly Expected Move ±5.6%
$35
$37
$39
$41
$44
Credit Risk of going bust: lower than 83% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Edgewise Therapeutics, Inc. would be worth roughly what it owes.
Total debt $3.6M against a stock market value of $4.21B.
Distance to default 10.49 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.8M (short-term plus half of long-term), stock volatility 72.0%; Altman Z'' 13.74. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Edgewise Therapeutics, Inc. would be worth roughly what it owes.
Total debt $3.6M against a stock market value of $4.21B.
Distance to default 10.49 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.8M (short-term plus half of long-term), stock volatility 72.0%; Altman Z'' 13.74. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
#86
of 1061
Biotechnology
Technical Signal Map
55 Bullish
7 Neutral
99 Bearish
EWTX
$4.2B
Edgewise Therapeutics, Inc.
BEARISH
-40
LZAGY
$54B
Lonza Group AG
BULLISH
+100
HALO
$14B
Halozyme Therapeutics, Inc.
BULLISH
+100
CAI
$9.1B
Caris Life Sciences, Inc.
BULLISH
+100
MANE
$5.8B
Veradermics, Incorporated
BULLISH
+100
VCEL
$2.2B
Vericel Corporation
BULLISH
+100
LKFT
$2.1B
Lakefront Biotherapeutics N.V.
BULLISH
+100
REGN
$83B
Regeneron Pharmaceuticals, Inc.
BULLISH
+91
ONC
$40B
BeOne Medicines AG
BULLISH
+91
EXEL
$16B
Exelixis, Inc.
BULLISH
+91
ARQT
$3.9B
Arcutis Biotherapeutics, Inc.
BULLISH
+91
BVNRY
$2.9B
Bavarian Nordic A/S
BULLISH
+91
FTRE
$2.2B
Fortrea Holdings Inc.
BULLISH
+91
AGIO
$2.2B
Agios Pharmaceuticals, Inc.
BULLISH
+91
ASND
$15B
Ascendis Pharma A/S
BULLISH
+87
UTHR
$25B
United Therapeutics Corporation
BULLISH
+84
LEGN
$3.6B
Legend Biotech Corporation
BULLISH
+84
VRDN
$2.5B
Viridian Therapeutics, Inc.
BULLISH
+78
AUPH
$2.2B
Aurinia Pharmaceuticals Inc.
BULLISH
+75
BHVN
$2.1B
Biohaven Ltd.
BULLISH
+75
GNMSF
$28B
Genmab A/S
BULLISH
+66
IRON
$2.9B
Disc Medicine, Inc.
BULLISH
+66
NRIX
$2.8B
Nurix Therapeutics, Inc.
BULLISH
+66
ZYME
$2.0B
Zymeworks Inc.
BULLISH
+66
XNCR
$1.9B
Xencor, Inc.
BULLISH
+66
KLRA
$1.7B
Kailera Therapeutics, Inc.
BULLISH
+66
TRAX
$1.6B
First Tracks Biotherapeutics Inc
BULLISH
+66
UCBJY
$58B
UCB S.A.
BULLISH
+62
ORKA
$5.3B
Oruka Therapeutics, Inc.
BULLISH
+62
NBIX
$15B
Neurocrine Biosciences, Inc.
BULLISH
+59
KYMR
$9.1B
Kymera Therapeutics, Inc.
BULLISH
+59
ERAS
$5.0B
Erasca, Inc.
BULLISH
+59
CSLLY
$134B
CSL Limited
BULLISH
+58
TECH
$11B
Bio-Techne Corporation
BULLISH
+58
ONTTF
$2.7B
Oxford Nanopore Technologies plc
BULLISH
+56
AKBLF
$7.4B
ALK-Abelló A/S
BULLISH
+53
ADMA
$2.4B
ADMA Biologics, Inc.
BULLISH
+53
BRVE
$1.5B
Braveheart Bio, Inc.
BULLISH
+51
ROIV
$26B
Roivant Sciences Ltd.
BULLISH
+50
SEPN
$1.9B
Septerna Inc
BULLISH
+50
MAZE
$1.7B
Maze Therapeutics, Inc.
BULLISH
+50
COAG
$1.6B
Hemab Therapeutics Holdings, Inc. Common Stock
BULLISH
+50
RARE
$1.5B
Ultragenyx Pharmaceutical Inc.
BULLISH
+43
SYRE
$8.3B
Spyre Therapeutics, Inc.
BULLISH
+42
IMCR
$1.6B
Immunocore Holdings plc
BULLISH
+41
XERS
$1.9B
Xeris Biopharma Holdings, Inc.
BULLISH
+40
NBTX
$1.5B
Nanobiotix S.A.
BULLISH
+35
VRTX
$133B
Vertex Pharmaceuticals Incorporated
BULLISH
+34
LGND
$6.0B
Ligand Pharmaceuticals Incorporated
BULLISH
+33
VIR
$1.8B
Vir Biotechnology, Inc.
BULLISH
+33
IOVA
$6.4B
Iovance Biotherapeutics, Inc.
BULLISH
+31
BBIO
$13B
BridgeBio Pharma, Inc.
LEAN BULL
+27
TGTX
$8.3B
TG Therapeutics, Inc.
LEAN BULL
+26
MRVI
$2.1B
Maravai LifeSciences Holdings, Inc.
LEAN BULL
+26
KOD
$5.5B
Kodiak Sciences Inc.
LEAN BULL
+18
RXRX
$2.0B
Recursion Pharmaceuticals, Inc.
LEAN BULL
+12
ZLAB
$2.7B
Zai Lab Limited
NEUTRAL
+8
AAVXF
$12B
Abivax S.A.
NEUTRAL
+2
PTGX
$9.0B
Protagonist Therapeutics, Inc.
NEUTRAL
+2
BCHMF
$6.8B
Bachem Holding AG
NEUTRAL
+2
LYCA
$1.6B
Lycia Therapeutics Inc.
N/A
0
PHMMF
$1.6B
Pharma Mar, S.A.
NEUTRAL
-3
ANAB
$1.5B
AnaptysBio, Inc.
NEUTRAL
-9
GLPGF
$2.1B
Lakefront Biotherapeutics
LEAN BEAR
-12
MRNA
$80B
Moderna, Inc.
LEAN BEAR
-13
COGT
$5.4B
Cogent Biosciences, Inc.
LEAN BEAR
-15
DFTX
$4.8B
Definium Therapeutics, Inc.
LEAN BEAR
-15
INVA
$1.5B
Innoviva, Inc.
LEAN BEAR
-15
RLAY
$4.0B
Relay Therapeutics, Inc.
LEAN BEAR
-16
NURPF
$1.8B
Neuren Pharmaceuticals Limited
LEAN BEAR
-17
ALMR
$2.1B
Alamar Biosciences, Inc.
LEAN BEAR
-19
HNGZY
$6.9B
Hangzhou Tigermed Consulting Co., Ltd
LEAN BEAR
-20
SHJBF
$4.8B
Shanghai Junshi Biosciences Co., Ltd.
LEAN BEAR
-20
CLDX
$2.3B
Celldex Therapeutics, Inc.
LEAN BEAR
-24
ZBIO
$1.8B
Zenas BioPharma, Inc.
LEAN BEAR
-24
SRRK
$5.0B
Scholar Rock Holding Corporation
LEAN BEAR
-27
ELVN
$3.0B
Enliven Therapeutics, Inc.
LEAN BEAR
-27
STOK
$1.6B
Stoke Therapeutics, Inc.
LEAN BEAR
-27
ABSI
$1.6B
Absci Corporation
BEARISH
-33
NTLA
$1.6B
Intellia Therapeutics, Inc.
BEARISH
-34
ARGX
$55B
argenx SE
BEARISH
-35
WXIBF
$26B
WuXi Biologics (Cayman) Inc.
BEARISH
-35
RYTM
$6.2B
Rhythm Pharmaceuticals, Inc.
BEARISH
-35
ACAD
$3.4B
Acadia Pharmaceuticals Inc.
BEARISH
-35
PVLA
$1.8B
Palvella Therapeutics, Inc.
BEARISH
-35
MEOBF
$2.0B
Mesoblast Limited
BEARISH
-37
INCY
$23B
Incyte Corporation
BEARISH
-40
ADPT
$4.1B
Adaptive Biotechnologies Corporation
BEARISH
-40
PHVS
$2.2B
Pharvaris N.V.
BEARISH
-40
SLS
$2.3B
SELLAS Life Sciences Group, Inc.
BEARISH
-42
SRPT
$1.9B
Sarepta Therapeutics, Inc.
BEARISH
-42
CSPHF
$1.4B
CStone Pharmaceuticals
BEARISH
-42
TNGX
$3.9B
Tango Therapeutics, Inc.
BEARISH
-43
IMNM
$2.1B
Immunome, Inc.
BEARISH
-44
ADRX
$1.9B
ADARx Pharmaceuticals, Inc.
BEARISH
-46
PCVX
$9.5B
Vaxcyte, Inc.
BEARISH
-47
XENE
$3.4B
Xenon Pharmaceuticals Inc.
BEARISH
-49
CELC
$3.2B
Celcuity Inc.
BEARISH
-49
DYN
$2.9B
Dyne Therapeutics, Inc.
BEARISH
-49
IVBXF
$20B
Innovent Biologics, Inc.
BEARISH
-50
AAPG
$1.4B
Ascentage Pharma Group International
BEARISH
-50
BMRN
$11B
BioMarin Pharmaceutical Inc.
BEARISH
-52
GNNSF
$9.6B
Genscript Biotech Corporation
BEARISH
-53
ALNY
$30B
Alnylam Pharmaceuticals, Inc.
BEARISH
-58
MIRM
$5.2B
Mirum Pharmaceuticals, Inc.
BEARISH
-58
TWST
$9.2B
Twist Bioscience Corporation
BEARISH
-59
ABCL
$3.8B
AbCellera Biologics Inc.
BEARISH
-59
CAMRF
$3.7B
Camurus AB
BEARISH
-59
DNTH
$4.3B
Dianthus Therapeutics, Inc.
BEARISH
-60
IDRSF
$1.4B
Idorsia Ltd
BEARISH
-60
RCUS
$2.3B
Arcus Biosciences, Inc.
BEARISH
-62
PRAX
$7.1B
Praxis Precision Medicines, Inc.
BEARISH
-65
RVMDW
$40B
Revolution Medicines, Inc. Warrant
BEARISH
-66
BEAM
$2.5B
Beam Therapeutics Inc.
BEARISH
-66
ARWR
$8.2B
Arrowhead Pharmaceuticals, Inc.
BEARISH
-69
IMVT
$5.9B
Immunovant, Inc.
BEARISH
-69
TRVI
$1.8B
Trevi Therapeutics, Inc.
BEARISH
-69
QURE
$1.6B
uniQure N.V.
BEARISH
-69
DNLI
$2.9B
Denali Therapeutics Inc.
BEARISH
-74
TXG
$9.3B
10x Genomics, Inc.
BEARISH
-75
BLTE
$5.9B
Belite Bio, Inc
BEARISH
-75
CGON
$5.5B
CG Oncology Inc.
BEARISH
-75
AMLX
$3.4B
Amylyx Pharmaceuticals, Inc.
BEARISH
-75
INCPF
$2.4B
InnoCare Pharma Limited
BEARISH
-75
BCRX
$1.9B
BioCryst Pharmaceuticals, Inc.
BEARISH
-75
GENB
$1.6B
Generate Biomedicines, Inc.
BEARISH
-75
CMPS
$1.6B
COMPASS Pathways plc
BEARISH
-75
CYTK
$8.5B
Cytokinetics, Incorporated
BEARISH
-82
VERA
$2.0B
Vera Therapeutics, Inc.
BEARISH
-82
RVMD
$40B
Revolution Medicines, Inc.
BEARISH
-84
BNTX
$22B
BioNTech SE
BEARISH
-84
KRYS
$9.2B
Krystal Biotech, Inc.
BEARISH
-84
CRSP
$4.8B
CRISPR Therapeutics AG
BEARISH
-84
IDYA
$3.4B
IDEAYA Biosciences, Inc.
BEARISH
-84
TARS
$3.2B
Tarsus Pharmaceuticals, Inc.
BEARISH
-84
TLX
$3.1B
Telix Pharmaceuticals Limited
BEARISH
-84
MBX
$2.3B
MBX Biosciences, Inc. Common Stock
BEARISH
-84
PGEN
$2.2B
Precigen, Inc.
BEARISH
-84
JAZZ
$14B
Jazz Pharmaceuticals plc
BEARISH
-87
MDGL
$10B
Madrigal Pharmaceuticals, Inc.
BEARISH
-87
IBRX
$8.7B
ImmunityBio, Inc.
BEARISH
-87
TVTX
$4.7B
Travere Therapeutics, Inc.
BEARISH
-87
BRCTF
$2.6B
BioArctic AB
BEARISH
-87
HRMY
$2.1B
Harmony Biosciences Holdings, Inc.
BEARISH
-87
URGN
$1.7B
UroGen Pharma Ltd.
BEARISH
-87
NVAX
$1.6B
Novavax, Inc.
BEARISH
-87
NUVB
$1.6B
Nuvation Bio Inc.
BEARISH
-87
INSM
$20B
Insmed Incorporated
BEARISH
-91
IONS
$7.1B
Ionis Pharmaceuticals, Inc.
BEARISH
-91
REGMF
$5.6B
RemeGen Co., Ltd.
BEARISH
-91
PTCT
$5.1B
PTC Therapeutics, Inc.
BEARISH
-91
PBLS
$3.0B
Parabilis Medicines, Inc.
BEARISH
-91
NAMS
$2.3B
NewAmsterdam Pharma Company N.V.
BEARISH
-91
SMMT
$12B
Summit Therapeutics Inc.
BEARISH
-100
AXSM
$7.6B
Axsome Therapeutics, Inc.
BEARISH
-100
TRSBF
$4.3B
3SBio Inc.
BEARISH
-100
VKTX
$3.1B
Viking Therapeutics, Inc.
BEARISH
-100
ZLDPF
$2.4B
Zealand Pharma A/S
BEARISH
-100
GENSF
$1.8B
Genus plc
BEARISH
-100
MLYS
$1.8B
Mineralys Therapeutics, Inc.
BEARISH
-100
OCUL
$1.4B
Ocular Therapeutix, Inc.
BEARISH
-100
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| EWTX Edgewise Therapeutics, Inc. | $4.2B | -21.4 | -38.0 | 1912.5 | — | — | 1 | BEARISH | 160.4 |
| LZAGY Lonza Group AG | $54B | -412.9 | 13.5 | 10.5 | 17.5 | -9.7 | 8 | BULLISH | 4.3 |
| HALO Halozyme Therapeutics, Inc. | $14B | 36.5 | 173.7 | 32.5 | 47.8 | 41.2 | 5 | BULLISH | 94.3 |
| CAI Caris Life Sciences, Inc. | $9.1B | 91.5 | 20.1 | 61.1 | -0.2 | 445.5 | 7 | BULLISH | 8.4 |
| MANE Veradermics, Incorporated | $5.8B | — | — | — | — | — | — | BULLISH | — |
| VCEL Vericel Corporation | $2.2B | 90.6 | 7.2 | 5.9 | 2.8 | 23.0 | 7 | BULLISH | 19.1 |
| LKFT Lakefront Biotherapeutics N.V. | $2.1B | — | — | — | — | — | — | BULLISH | — |
| REGN Regeneron Pharmaceuticals, Inc. | $83B | 19.4 | 14.0 | 12.9 | 30.2 | 9.3 | 7 | BULLISH | 41.4 |
| ONC BeOne Medicines AG | $40B | 25.2 | 14.7 | 57.2 | 13.9 | 34.3 | 8 | BULLISH | 17.9 |
| EXEL Exelixis, Inc. | $16B | 19.8 | 44.4 | 69.0 | 33.7 | 9.2 | 8 | BULLISH | 68.8 |
| ARQT Arcutis Biotherapeutics, Inc. | $3.9B | 143.7 | 15.9 | 34.7 | 11.6 | 76.1 | 7 | BULLISH | 57.5 |
| BVNRY Bavarian Nordic A/S | $2.9B | 13.0 | 12.3 | 7.1 | 36.0 | -5.8 | 7 | BULLISH | 1.9 |
| FTRE Fortrea Holdings Inc. | $2.2B | -26.2 | -15.3 | 0.6 | -1.9 | -2.1 | 6 | BULLISH | 116.2 |
| AGIO Agios Pharmaceuticals, Inc. | $2.2B | -5.4 | -34.3 | -82.5 | -225.1 | 140.6 | 4 | BULLISH | -12.2 |
| ASND Ascendis Pharma A/S | $15B | 18.2 | 121.1 | 76.2 | 61.0 | 114.8 | 7 | BULLISH | 21.7 |
| UTHR United Therapeutics Corporation | $25B | 19.5 | 19.3 | 31.3 | 42.5 | 2.5 | 6 | BULLISH | 41.2 |
| LEGN Legend Biotech Corporation | $3.6B | -42.9 | -8.1 | -8.2 | 8.6 | 59.5 | 4 | BULLISH | -32.3 |
| VRDN Viridian Therapeutics, Inc. | $2.5B | -6.7 | -65.7 | 418.2 | -44760.2 | 23220.3 | 4 | BULLISH | 8.7 |
| AUPH Aurinia Pharmaceuticals Inc. | $2.2B | 7.3 | 66.1 | 127.2 | 45.0 | 19.8 | 7 | BULLISH | 45.1 |
| BHVN Biohaven Ltd. | $2.1B | -3.3 | -799.5 | -1083.0 | — | — | 3 | BULLISH | -7.9 |
| GNMSF Genmab A/S | $28B | 34.9 | 3.9 | 11.9 | 26.2 | -82.1 | 4 | BULLISH | 47.7 |
| IRON Disc Medicine, Inc. | $2.9B | -12.1 | -39.1 | 1672.3 | — | — | 1 | BULLISH | -6.7 |
| NRIX Nurix Therapeutics, Inc. | $2.8B | 10.6 | 44.0 | -1896.6 | 81.7 | 738.8 | 8 | BULLISH | 140.8 |
| ZYME Zymeworks Inc. | $2.0B | -14.3 | -72.3 | -156.9 | -980.8 | -69.8 | 2 | BULLISH | 62.6 |
| XNCR Xencor, Inc. | $1.9B | -13.7 | -29.1 | -152.4 | -42.4 | -36.1 | 2 | BULLISH | 127.0 |
| KLRA Kailera Therapeutics, Inc. | $1.7B | — | — | — | — | — | — | BULLISH | — |
| TRAX First Tracks Biotherapeutics Inc | $1.6B | — | — | — | — | — | — | BULLISH | — |
| UCBJY UCB S.A. | $58B | 23.3 | 20.7 | 16.4 | 26.0 | 25.3 | 6 | BULLISH | 5.8 |
| ORKA Oruka Therapeutics, Inc. | $5.3B | -38.6 | -18.2 | -50.3 | — | — | 4 | BULLISH | 251.6 |
| NBIX Neurocrine Biosciences, Inc. | $15B | 20.6 | 22.1 | 16.0 | 15.1 | 34.4 | 6 | BULLISH | 1.4 |
| KYMR Kymera Therapeutics, Inc. | $9.1B | -36.7 | -24.2 | -30.7 | -94.2 | 134.8 | 6 | BULLISH | 100.8 |
| ERAS Erasca, Inc. | $5.0B | -15.8 | -78.2 | -87.5 | — | — | 2 | BULLISH | 539.5 |
| CSLLY CSL Limited | $134B | -26.1 | -15.2 | 13.1 | -40.2 | 1.7 | 4 | BULLISH | 1.4 |
| TECH Bio-Techne Corporation | $11B | 62.1 | 9.0 | 8.9 | 17.0 | -0.4 | 7 | BULLISH | 10.3 |
| ONTTF Oxford Nanopore Technologies plc | $2.7B | -18.0 | -25.6 | -36.2 | -41.1 | 14.4 | 4 | BULLISH | 41.7 |
| AKBLF ALK-Abelló A/S | $7.4B | 39.9 | 21.2 | 23.9 | 18.9 | 16.4 | 8 | BULLISH | 12.8 |
| ADMA ADMA Biologics, Inc. | $2.4B | 15.4 | 41.9 | 35.5 | 30.4 | 8.0 | 5 | BULLISH | -26.4 |
| BRVE Braveheart Bio, Inc. | $1.5B | — | — | — | — | — | — | BULLISH | — |
| ROIV Roivant Sciences Ltd. | $26B | -95.9 | -6.2 | -217.5 | -13164.4 | -67.6 | 1 | BULLISH | 100.5 |
| SEPN Septerna Inc | $1.9B | -81.5 | -6.3 | -93.1 | -48.7 | 17878.5 | 5 | BULLISH | 103.7 |
| MAZE Maze Therapeutics, Inc. | $1.7B | -11.4 | -37.3 | -112.3 | — | — | 3 | BULLISH | 4.3 |
| COAG Hemab Therapeutics Holdings, Inc. Common Stock | $1.6B | — | — | — | — | — | — | BULLISH | — |
| RARE Ultragenyx Pharmaceutical Inc. | $1.5B | -2.9 | 839.4 | -67.5 | -43.0 | 17.5 | 2 | BULLISH | -50.0 |
| SYRE Spyre Therapeutics, Inc. | $8.3B | -50.4 | -23.0 | 359.8 | — | — | 3 | BULLISH | 323.8 |
| IMCR Immunocore Holdings plc | $1.6B | -176.2 | -2.3 | -472.0 | -0.7 | 13.4 | 4 | BULLISH | -3.4 |
| XERS Xeris Biopharma Holdings, Inc. | $1.9B | -107.0 | 118.2 | 18.3 | -33.8 | 36.3 | 6 | BULLISH | 13.5 |
| NBTX Nanobiotix S.A. | $1.5B | -27.5 | 104.2 | 62.0 | -626.0 | 49.1 | 4 | BULLISH | 79.8 |
| VRTX Vertex Pharmaceuticals Incorporated | $133B | 29.9 | 23.5 | 28.3 | 33.0 | 10.6 | 6 | BULLISH | 23.6 |
| LGND Ligand Pharmaceuticals Incorporated | $6.0B | 31.2 | 22.0 | 11.3 | 76.2 | 54.9 | 5 | BULLISH | 66.7 |
| VIR Vir Biotechnology, Inc. | $1.8B | -6.2 | -26.1 | -38.8 | 33.5 | 1495.9 | 5 | BULLISH | 93.5 |
| IOVA Iovance Biotherapeutics, Inc. | $6.4B | -20.1 | -40.4 | -49.1 | -47.6 | 34.5 | 6 | BULLISH | 548.0 |
| BBIO BridgeBio Pharma, Inc. | $13B | -19.3 | 32.4 | 57.9 | -62.5 | 202.4 | 4 | LEAN BULL | 27.9 |
| TGTX TG Therapeutics, Inc. | $8.3B | 18.5 | 100.3 | 73.5 | 3.2 | 76.1 | 6 | LEAN BULL | 69.3 |
| MRVI Maravai LifeSciences Holdings, Inc. | $2.1B | -15.3 | -32.9 | 24.4 | -24.1 | -3.3 | 5 | LEAN BULL | 142.2 |
| KOD Kodiak Sciences Inc. | $5.5B | -21.7 | -368.4 | -630.1 | — | — | 1 | LEAN BULL | 388.6 |
| RXRX Recursion Pharmaceuticals, Inc. | $2.0B | -3.9 | -56.6 | -99.7 | -1708.0 | -14.9 | 4 | LEAN BULL | -33.0 |
| ZLAB Zai Lab Limited | $2.7B | -13.3 | -26.9 | -85.4 | -47.8 | 5.1 | 3 | NEUTRAL | -10.4 |
| AAVXF Abivax S.A. | $12B | -17.0 | -221.8 | 440.6 | — | -133.5 | 4 | NEUTRAL | 57.0 |
| PTGX Protagonist Therapeutics, Inc. | $9.0B | 115.5 | 11.0 | 84.1 | 76.3 | 34.8 | 7 | NEUTRAL | 88.5 |
| BCHMF Bachem Holding AG | $6.8B | 41.9 | 10.6 | 8.2 | 15.4 | 4.3 | 3 | NEUTRAL | 24.7 |
| LYCA Lycia Therapeutics Inc. | $1.6B | — | — | — | — | — | — | N/A | — |
| PHMMF Pharma Mar, S.A. | $1.6B | 21.2 | 24.9 | 35.9 | -2.0 | 15.5 | 7 | NEUTRAL | 1.7 |
| ANAB AnaptysBio, Inc. | $1.5B | 7.3 | -1146.3 | 466.0 | 668.9 | 92.9 | 5 | NEUTRAL | 112.3 |
| GLPGF Lakefront Biotherapeutics | $2.1B | 3.8 | 20.2 | 39.4 | 17.4 | 259.3 | 5 | LEAN BEAR | -4.5 |
| MRNA Moderna, Inc. | $80B | -25.8 | -39.0 | -90.1 | -539.3 | -27.2 | 2 | LEAN BEAR | 724.0 |
| COGT Cogent Biosciences, Inc. | $5.4B | -13.9 | -109.7 | 1964.0 | — | — | 3 | LEAN BEAR | 111.6 |
| DFTX Definium Therapeutics, Inc. | $4.8B | -10.8 | -25.7 | 82.4 | — | — | 2 | LEAN BEAR | — |
| INVA Innoviva, Inc. | $1.5B | 4.3 | 36.7 | 15.0 | -69.8 | 19.8 | 7 | LEAN BEAR | 18.2 |
| RLAY Relay Therapeutics, Inc. | $4.0B | -12.0 | -36.8 | -2519.7 | -23916.3 | 23.9 | 4 | LEAN BEAR | 174.6 |
| NURPF Neuren Pharmaceuticals Limited | $1.8B | 118.1 | 6.2 | 22.4 | 14.6 | -68.5 | 5 | LEAN BEAR | 20.8 |
| ALMR Alamar Biosciences, Inc. | $2.1B | — | — | — | — | — | — | LEAN BEAR | — |
| HNGZY Hangzhou Tigermed Consulting Co., Ltd | $6.9B | 597.8 | 0.5 | 1.6 | -24.2 | 12.0 | 6 | LEAN BEAR | 11.2 |
| SHJBF Shanghai Junshi Biosciences Co., Ltd. | $4.8B | -69.3 | -7.1 | -6.3 | 4.4 | 29.7 | 5 | LEAN BEAR | -20.8 |
| CLDX Celldex Therapeutics, Inc. | $2.3B | -6.9 | -43.9 | -13685.9 | -334104.5 | -98.1 | 1 | LEAN BEAR | 12.8 |
| ZBIO Zenas BioPharma, Inc. | $1.8B | -2.9 | -199.0 | 5842.1 | -11145.6 | -93.3 | 2 | LEAN BEAR | 14.2 |
| SRRK Scholar Rock Holding Corporation | $5.0B | -12.8 | -167.8 | 931.3 | — | — | 2 | LEAN BEAR | 43.2 |
| ELVN Enliven Therapeutics, Inc. | $3.0B | -26.5 | -15.3 | -6535.0 | — | — | 3 | LEAN BEAR | 112.0 |
| STOK Stoke Therapeutics, Inc. | $1.6B | -7.8 | -61.1 | -318.5 | -660.8 | -86.2 | 2 | LEAN BEAR | -19.1 |
| ABSI Absci Corporation | $1.6B | -13.4 | -57.7 | -213.1 | -10443.4 | -62.3 | 5 | BEARISH | 147.5 |
| NTLA Intellia Therapeutics, Inc. | $1.6B | -3.6 | -55.4 | -92.1 | -1392.3 | 12.6 | 5 | BEARISH | -52.0 |
| ARGX argenx SE | $55B | 41.0 | 26.0 | 50.1 | 29.8 | 162.5 | 7 | BEARISH | 8.0 |
| WXIBF WuXi Biologics (Cayman) Inc. | $26B | 31.4 | 10.6 | 16.0 | 20.7 | 16.0 | 9 | BEARISH | 20.2 |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.2B | -29.5 | -200.0 | 144.2 | -69.2 | 53.5 | 4 | BEARISH | -16.6 |
| ACAD Acadia Pharmaceuticals Inc. | $3.4B | 9.0 | 35.7 | 63.9 | 10.2 | 11.8 | 5 | BEARISH | -8.4 |
| PVLA Palvella Therapeutics, Inc. | $1.8B | -27.4 | -46.6 | 137.5 | — | — | 3 | BEARISH | 82.1 |
| MEOBF Mesoblast Limited | $2.0B | -29.4 | -9.9 | -14.4 | -23.4 | 613.8 | 5 | BEARISH | -20.0 |
| INCY Incyte Corporation | $23B | 14.3 | 30.7 | 82.1 | 35.0 | 26.9 | 8 | BEARISH | 27.7 |
| ADPT Adaptive Biotechnologies Corporation | $4.1B | -68.5 | -39.6 | -14.1 | -55.6 | 50.1 | 5 | BEARISH | 60.6 |
| PHVS Pharvaris N.V. | $2.2B | -10.6 | -70.7 | 860.9 | — | — | 4 | BEARISH | 39.0 |
| SLS SELLAS Life Sciences Group, Inc. | $2.3B | -57.2 | -39.6 | 55646.0 | — | — | 4 | BEARISH | 511.6 |
| SRPT Sarepta Therapeutics, Inc. | $1.9B | -13.0 | -9.5 | -6.3 | -1.2 | -20.4 | 4 | BEARISH | -17.2 |
| CSPHF CStone Pharmaceuticals | $1.4B | -14.4 | -51.4 | -340.2 | -123.0 | 135.6 | 5 | BEARISH | -15.4 |
| TNGX Tango Therapeutics, Inc. | $3.9B | -27.3 | -21.3 | -253.2 | — | 121.5 | 3 | BEARISH | 205.2 |
| IMNM Immunome, Inc. | $2.1B | -7.4 | -64.0 | -2208.4 | — | -100.0 | 4 | BEARISH | 19.6 |
| ADRX ADARx Pharmaceuticals, Inc. | $1.9B | — | — | — | — | — | — | BEARISH | — |
| PCVX Vaxcyte, Inc. | $9.5B | -8.0 | -36.5 | -66.4 | — | — | 0 | BEARISH | 43.7 |
| XENE Xenon Pharmaceuticals Inc. | $3.4B | -7.6 | -43.6 | -109.7 | — | -100.0 | 3 | BEARISH | -11.7 |
| CELC Celcuity Inc. | $3.2B | -16.0 | -1433.7 | 1325.2 | — | — | 3 | BEARISH | -4.1 |
| DYN Dyne Therapeutics, Inc. | $2.9B | -5.1 | -81.6 | 240.4 | — | — | 2 | BEARISH | -1.1 |
| IVBXF Innovent Biologics, Inc. | $20B | 96.9 | 6.9 | 67.2 | 14.5 | 35.4 | 6 | BEARISH | -11.4 |
| AAPG Ascentage Pharma Group International | $1.4B | -6.1 | -236.8 | -144.8 | -270.2 | 170.9 | 3 | BEARISH | -58.7 |
| BMRN BioMarin Pharmaceutical Inc. | $11B | 146.2 | 1.2 | 1.4 | 4.5 | 11.2 | 4 | BEARISH | 1.6 |
| GNNSF Genscript Biotech Corporation | $9.6B | -14.1 | -15.4 | 2.9 | -32.0 | 53.1 | 4 | BEARISH | 97.7 |
| ALNY Alnylam Pharmaceuticals, Inc. | $30B | 37.2 | 100.7 | -152.8 | 12.7 | 95.1 | 6 | BEARISH | -51.1 |
| MIRM Mirum Pharmaceuticals, Inc. | $5.2B | -5.9 | -703.0 | -27.3 | -38.1 | 44.0 | 3 | BEARISH | 22.2 |
| TWST Twist Bioscience Corporation | $9.2B | -71.7 | -29.6 | -29.2 | -29.6 | 19.2 | 2 | BEARISH | 368.6 |
| ABCL AbCellera Biologics Inc. | $3.8B | -23.5 | -17.3 | -36.2 | -1368.6 | 101.3 | 4 | BEARISH | 126.7 |
| CAMRF Camurus AB | $3.7B | 58.2 | 15.8 | 89.3 | 34.3 | -0.2 | 6 | BEARISH | -10.3 |
| DNTH Dianthus Therapeutics, Inc. | $4.3B | -610.5 | -4.1 | -60.1 | -6598.6 | -60.8 | 3 | BEARISH | 141.6 |
| IDRSF Idorsia Ltd | $1.4B | -3.5 | 27.1 | -344.5 | -203.1 | -8.1 | 1 | BEARISH | 19.6 |
| RCUS Arcus Biosciences, Inc. | $2.3B | -4.6 | -89.2 | 309.6 | -222.0 | -55.3 | 0 | BEARISH | 4.8 |
| PRAX Praxis Precision Medicines, Inc. | $7.1B | -20.8 | -38.9 | -51.2 | — | -100.0 | 4 | BEARISH | 53.8 |
| RVMDW Revolution Medicines, Inc. Warrant | $40B | -21.0 | -79.1 | 186.4 | — | — | 1 | BEARISH | 2251.5 |
| BEAM Beam Therapeutics Inc. | $2.5B | -30.2 | -8.1 | -184.5 | -25036.3 | 158.9 | 4 | BEARISH | -10.9 |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.2B | -26.6 | -64.8 | 65.7 | -258.2 | 12.2 | 4 | BEARISH | 55.3 |
| IMVT Immunovant, Inc. | $5.9B | -10.2 | -80.1 | 707.5 | -2159.6 | — | 2 | BEARISH | 52.5 |
| TRVI Trevi Therapeutics, Inc. | $1.8B | -39.6 | -19.7 | -1451.7 | — | — | 3 | BEARISH | 27.0 |
| QURE uniQure N.V. | $1.6B | -5.9 | -157.6 | 37.9 | -1387.8 | 30.2 | 4 | BEARISH | -60.2 |
| DNLI Denali Therapeutics Inc. | $2.9B | -6.7 | -54.9 | -281.7 | -3539.2 | — | 3 | BEARISH | 20.4 |
| TXG 10x Genomics, Inc. | $9.3B | -132.5 | -9.4 | -19.8 | -11.9 | -4.3 | 5 | BEARISH | 466.6 |
| BLTE Belite Bio, Inc | $5.9B | -52.9 | -20.8 | -11.5 | — | — | 3 | BEARISH | 57.0 |
| CGON CG Oncology Inc. | $5.5B | -23.5 | -26.4 | -2066.1 | -6832.8 | 1030.3 | 3 | BEARISH | 44.1 |
| AMLX Amylyx Pharmaceuticals, Inc. | $3.4B | -19.9 | -74.7 | 2020.5 | — | 100.0 | 5 | BEARISH | 99.7 |
| INCPF InnoCare Pharma Limited | $2.4B | 18.7 | 12.6 | 45.8 | 23.1 | 108.5 | 4 | BEARISH | -50.9 |
| BCRX BioCryst Pharmaceuticals, Inc. | $1.9B | -5.6 | 87.8 | 62.3 | 35.9 | 68.7 | 5 | BEARISH | 12.5 |
| GENB Generate Biomedicines, Inc. | $1.6B | -7.9 | -28.2 | -175.0 | -1065.2 | — | 1 | BEARISH | — |
| CMPS COMPASS Pathways plc | $1.6B | -2.1 | -319.1 | 48.8 | — | — | 2 | BEARISH | 88.1 |
| CYTK Cytokinetics, Incorporated | $8.5B | -8.5 | 329.8 | 811.2 | -622.8 | -17.2 | 2 | BEARISH | 6.4 |
| VERA Vera Therapeutics, Inc. | $2.0B | -5.1 | -91.8 | 2030.6 | — | — | 1 | BEARISH | 2.6 |
| RVMD Revolution Medicines, Inc. | $40B | -21.0 | -79.1 | 186.4 | — | — | 1 | BEARISH | 241.8 |
| BNTX BioNTech SE | $22B | -11.5 | -9.3 | -18.0 | -777.3 | -8.2 | 2 | BEARISH | -17.6 |
| KRYS Krystal Biotech, Inc. | $9.2B | 38.6 | 20.1 | 40.4 | 45.9 | 22.6 | 7 | BEARISH | 72.2 |
| CRSP CRISPR Therapeutics AG | $4.8B | -10.7 | -26.1 | -253.2 | -895.3 | -62.7 | 3 | BEARISH | -23.9 |
| IDYA IDEAYA Biosciences, Inc. | $3.4B | -17.4 | -16.2 | -42.9 | -1269.6 | 3244.7 | 4 | BEARISH | 14.8 |
| TARS Tarsus Pharmaceuticals, Inc. | $3.2B | -65.1 | -13.7 | 268.1 | -10.7 | 105.2 | 5 | BEARISH | 7.1 |
| TLX Telix Pharmaceuticals Limited | $3.1B | 92.5 | 8.6 | -1.0 | 8.0 | 10.5 | 4 | BEARISH | -16.5 |
| MBX MBX Biosciences, Inc. Common Stock | $2.3B | -22.1 | -33.2 | 1634.0 | — | — | 2 | BEARISH | 211.6 |
| PGEN Precigen, Inc. | $2.2B | -5.4 | -4640.4 | -30.1 | 36.5 | 1875.0 | 5 | BEARISH | 42.0 |
| JAZZ Jazz Pharmaceuticals plc | $14B | 13.6 | 22.1 | 26.4 | 16.0 | 12.6 | 8 | BEARISH | 49.3 |
| MDGL Madrigal Pharmaceuticals, Inc. | $10B | -34.1 | -53.3 | -778.9 | -15.9 | 149.0 | 2 | BEARISH | 4.5 |
| IBRX ImmunityBio, Inc. | $8.7B | -8.8 | 122.7 | 33.7 | -449.6 | 192.9 | 4 | BEARISH | 249.4 |
| TVTX Travere Therapeutics, Inc. | $4.7B | -112.6 | -151.8 | -21.0 | -20.5 | 77.1 | 6 | BEARISH | 81.3 |
| BRCTF BioArctic AB | $2.6B | 263.7 | 5.2 | 77.4 | -4.5 | -46.1 | 3 | BEARISH | -8.6 |
| HRMY Harmony Biosciences Holdings, Inc. | $2.1B | 12.0 | 20.5 | 35.7 | 28.9 | 24.3 | 5 | BEARISH | 25.4 |
| URGN UroGen Pharma Ltd. | $1.7B | -17.2 | 86.5 | 119.0 | -19.8 | 169.5 | 2 | BEARISH | 78.8 |
| NVAX Novavax, Inc. | $1.6B | -6.6 | 323.7 | 29.2 | -94.2 | -61.6 | 2 | BEARISH | 17.6 |
| NUVB Nuvation Bio Inc. | $1.6B | -10.3 | -47.8 | 70.2 | -198.3 | 1083.6 | 4 | BEARISH | -6.2 |
| INSM Insmed Incorporated | $20B | -23.0 | -87.2 | -364.8 | -3.1 | 185.8 | 5 | BEARISH | -40.5 |
| IONS Ionis Pharmaceuticals, Inc. | $7.1B | -12.7 | -105.4 | -58.5 | -42.8 | -7.4 | 3 | BEARISH | -38.0 |
| REGMF RemeGen Co., Ltd. | $5.6B | 9.1 | 108.3 | 139.6 | 83.4 | 283.6 | 7 | BEARISH | -7.7 |
| PTCT PTC Therapeutics, Inc. | $5.1B | -126.1 | 20.6 | -5.4 | 23.2 | -42.8 | 2 | BEARISH | -6.5 |
| PBLS Parabilis Medicines, Inc. | $3.0B | — | — | — | — | — | — | BEARISH | — |
| NAMS NewAmsterdam Pharma Company N.V. | $2.3B | -9.4 | -36.8 | 8216.2 | -1732.9 | -88.9 | 2 | BEARISH | -42.6 |
| SMMT Summit Therapeutics Inc. | $12B | -13.7 | -192.5 | 1714.4 | — | — | 3 | BEARISH | -20.5 |
| AXSM Axsome Therapeutics, Inc. | $7.6B | -37.9 | -245.1 | 859.1 | -23.5 | 56.9 | 5 | BEARISH | 9.8 |
| TRSBF 3SBio Inc. | $4.3B | 3.4 | 37.1 | 80.3 | 25.3 | 93.8 | 7 | BEARISH | -51.7 |
| VKTX Viking Therapeutics, Inc. | $3.1B | -5.3 | -88.9 | 495.6 | — | — | 1 | BEARISH | -27.7 |
| ZLDPF Zealand Pharma A/S | $2.4B | 5.8 | 16.3 | 57.2 | 87.2 | -49.2 | 3 | BEARISH | -54.1 |
| GENSF Genus plc | $1.8B | 5.4 | 45.4 | 9.0 | 80.4 | -3.8 | 5 | BEARISH | -19.4 |
| MLYS Mineralys Therapeutics, Inc. | $1.8B | -4.9 | -80.9 | 2274.6 | — | — | 2 | BEARISH | -47.0 |
| OCUL Ocular Therapeutix, Inc. | $1.4B | -4.7 | -73.0 | -31671.3 | -584.5 | -8.1 | 3 | BEARISH | -41.5 |
| EWTX Edgewise Therapeutics, Inc. | $4.2B | -21.4 | -38.0 | 1912.5 | — | — | 1 | BEARISH | 160.4 |
| HKMPY Hikma Pharmaceuticals PLC | $4.6B | 12.7 | 15.3 | 12.1 | 12.9 | 6.1 | 7 | BULLISH | -5.2 |
| IRTC iRhythm Technologies, Inc. | $4.0B | -287.0 | -9.6 | -3.4 | -0.2 | 25.6 | 6 | BULLISH | -31.5 |
| DSRLF DiaSorin S.p.A. | $4.4B | 25.1 | 14.2 | 8.9 | 14.0 | 46.3 | 5 | BULLISH | -2.4 |
| VCYT Veracyte, Inc. | $3.9B | 35.8 | 8.8 | 10.7 | 17.0 | 17.3 | 8 | BULLISH | 36.9 |
| MAHLY MediPal Holdings Corporation | $4.1B | 15.1 | 7.5 | 8.7 | 1.4 | 5.9 | 7 | BULLISH | 23.9 |
| LIVN LivaNova PLC | $4.4B | 23.3 | 15.4 | 30.2 | 27.8 | 12.4 | 8 | BULLISH | 46.4 |
| ICUI ICU Medical, Inc. | $4.2B | 136.5 | 1.4 | 2.7 | 3.5 | -9.0 | 6 | BULLISH | 32.2 |
| LQDA Liquidia Corporation | $3.8B | 29.0 | 131.8 | 391.9 | 43.5 | 2233.6 | 6 | BULLISH | 103.0 |
| APNHY Aspen Pharmacare Holdings Limited | $4.2B | 26.9 | 3.2 | 5.3 | 6.6 | -20.1 | 7 | BULLISH | 69.4 |
| NVST Envista Holdings Corp | $3.8B | 40.2 | 3.1 | 3.2 | 7.4 | 11.9 | 7 | LEAN BULL | 15.9 |
| ITGR Integer Holdings Corporation | $4.3B | 34.3 | 7.5 | 5.4 | 5.1 | 2.6 | 7 | NEUTRAL | 73.8 |
| TSUSF Tsuruha Holdings Inc. | $4.2B | 17.4 | 6.2 | 12.0 | 2.8 | 16.1 | 5 | NEUTRAL | 0.0 |
| SGFEF Siegfried Holding AG | $3.9B | 19.2 | 17.0 | 9.4 | 10.8 | 3.4 | 4 | NEUTRAL | -15.8 |
| GEDSF Gedeon Richter PLC | $4.5B | 10.7 | 16.4 | 22.0 | 29.6 | 4.8 | 7 | LEAN BEAR | 0.0 |
| MCVEF Medicover AB (publ) | $4.1B | 44.6 | 16.9 | 6.8 | 3.8 | 9.4 | 7 | LEAN BEAR | 0.0 |
| INDV Indivior Pharmaceuticals Inc | $4.3B | 12.1 | -152.4 | 528.3 | 35.6 | 13.5 | 4 | BEARISH | 38.2 |
| RGC Regencell Bioscience Holdings Limited | $3.8B | -311.9 | -128.5 | 1692.4 | — | — | 3 | BEARISH | -53.1 |
| ALVOW Alvotech | $3.9B | -8.1 | 98.5 | 3.3 | -63.2 | -12.2 | 0 | BEARISH | -85.2 |
| HYPMY Hypera S.A. | $3.8B | 7.9 | 13.2 | 12.8 | 21.0 | 31.8 | 8 | BEARISH | -2.2 |
| RTEZ Rest Ez Inc. | $4.2B | — | — | — | — | — | — | BEARISH | 0.0 |
| EWTX Edgewise Therapeutics, Inc. | $4.2B | -21.4 | -38.0 | 1912.5 | — | — | 1 | BEARISH | 160.4 |
| MDT Medtronic Plc | $122B | 23.0 | 10.7 | 7.8 | 15.1 | 9.8 | 9 | BULLISH | 3.6 |
| LZAGY Lonza Group AG | $54B | -412.9 | 13.5 | 10.5 | 17.5 | -9.7 | 8 | BULLISH | 4.3 |
| ORINY Orion Oyj | $30B | 23.0 | 53.6 | 46.3 | 26.9 | 22.6 | 7 | BULLISH | 44.0 |
| RPRX Royalty Pharma plc | $28B | 27.1 | 12.4 | 10.6 | 2.7 | 10.0 | 6 | BULLISH | 76.2 |
| LH Labcorp Holdings Inc. | $27B | 27.0 | 11.7 | 8.6 | 8.0 | 6.4 | 8 | BULLISH | 19.8 |
| ZBH Zimmer Biomet Holdings, Inc. | $19B | 23.4 | 6.4 | 5.9 | 9.1 | 8.6 | 6 | BULLISH | -6.8 |
| MEDP Medpace Holdings, Inc. | $19B | 36.7 | 117.9 | 1953.7 | 19.2 | 20.4 | 9 | BULLISH | 11.3 |
| CRL Charles River Laboratories International, Inc. | $17B | -73.8 | -7.7 | 6.9 | -0.1 | -0.7 | 4 | BULLISH | 82.2 |
| HALO Halozyme Therapeutics, Inc. | $14B | 36.5 | 173.7 | 32.5 | 47.8 | 41.2 | 5 | BULLISH | 94.3 |
| QGEN Qiagen N.V. | $10B | 25.8 | 11.9 | 11.2 | 19.3 | 3.0 | 8 | BULLISH | 1.7 |
| CAI Caris Life Sciences, Inc. | $9.1B | 91.5 | 20.1 | 61.1 | -0.2 | 445.5 | 7 | BULLISH | 8.4 |
| RGEDF Chemical Works of Gedeon Richter Plc | $7.4B | 10.7 | 16.2 | 24.3 | 15.9 | 1.8 | 5 | BULLISH | 32.8 |
| ALKS Alkermes plc | $7.3B | 110.1 | 3.9 | 2.9 | 0.1 | 10.8 | 4 | BULLISH | 48.7 |
| AMRX Amneal Pharmaceuticals, Inc. | $6.5B | 43.0 | -395.8 | 16.0 | 7.2 | 9.3 | 8 | BULLISH | 103.2 |
| MANE Veradermics, Incorporated | $5.8B | — | — | — | — | — | — | BULLISH | — |
| TFX Teleflex Incorporated | $5.8B | -5.9 | -28.8 | 1.3 | 17.9 | -14.5 | 5 | BULLISH | 5.8 |
| MMSI Merit Medical Systems, Inc. | $5.6B | 38.2 | 9.2 | 7.3 | 9.3 | 10.2 | 9 | BULLISH | 13.0 |
| CON Concentra Group Holdings Parent, Inc. | $5.0B | 25.7 | 48.5 | 66.4 | 10.8 | 14.0 | 9 | BULLISH | 92.0 |
| LFST LifeStance Health Group, Inc. | $4.9B | 101.0 | 3.4 | 4.1 | 5.4 | 20.4 | 7 | BULLISH | 151.9 |
| ATRC AtriCure, Inc. | $3.0B | 289.6 | 2.2 | 2.9 | 5.8 | 13.9 | 8 | BULLISH | 63.9 |
| GNNDY GN Store Nord A/S | $2.4B | -29.9 | -5.4 | 1.6 | -1.0 | -25.4 | 4 | BULLISH | -5.1 |
| VCEL Vericel Corporation | $2.2B | 90.6 | 7.2 | 5.9 | 2.8 | 23.0 | 7 | BULLISH | 19.1 |
| LKFT Lakefront Biotherapeutics N.V. | $2.1B | — | — | — | — | — | — | BULLISH | — |
| PFE Pfizer Inc. | $171B | 39.3 | 5.0 | 11.3 | -1.6 | -0.2 | 7 | BULLISH | 22.5 |
| DHR Danaher Corporation | $162B | 37.9 | 8.3 | 6.3 | 18.8 | 5.5 | 7 | BULLISH | 4.8 |
| CVS CVS Health Corp. | $120B | 23.8 | 6.2 | 4.9 | 2.8 | 7.4 | 8 | BULLISH | 11.2 |
| MCK McKesson Corporation | $117B | 25.8 | -148.0 | 237.7 | 0.6 | 8.8 | 8 | BULLISH | 20.7 |
| ELV Elevance Health Inc. | $95B | 17.9 | 11.6 | 16.2 | 2.7 | 3.6 | 7 | BULLISH | 23.7 |
| REGN Regeneron Pharmaceuticals, Inc. | $83B | 19.4 | 14.0 | 12.9 | 30.2 | 9.3 | 7 | BULLISH | 41.4 |
| CI Cigna Corporation | $81B | 12.3 | 15.5 | 11.8 | 2.3 | 7.7 | 8 | BULLISH | -0.6 |
| TKPHF Takeda Pharmaceutical Company Limited | $66B | 56.1 | 2.5 | 2.8 | 9.3 | 3.3 | 6 | BULLISH | 41.6 |
| CAH Cardinal Health, Inc. | $58B | 34.0 | -60.5 | 92.8 | 0.6 | 14.2 | 8 | BULLISH | 53.7 |
| BDX Becton, Dickinson and Company | $54B | 58.9 | 3.8 | 4.1 | 7.6 | -2.6 | 6 | BULLISH | 5.5 |
| SDZNY Sandoz Group AG | $42B | 66.5 | 7.2 | 10.1 | 1.9 | 29.1 | 6 | BULLISH | 59.1 |
| OTSKY Otsuka Holdings Co., Ltd. | $42B | 16.0 | 13.8 | 12.2 | 16.7 | 10.9 | 8 | BULLISH | 44.2 |
| ONC BeOne Medicines AG | $40B | 25.2 | 14.7 | 57.2 | 13.9 | 34.3 | 8 | BULLISH | 17.9 |
| CNC Centene Corp. | $35B | 23.2 | 6.8 | 6.4 | -0.1 | 4.8 | 8 | BULLISH | 101.6 |
| MTD Mettler-Toledo International Inc. | $33B | 37.8 | -736.4 | 46.7 | 22.7 | 6.9 | 8 | BULLISH | 17.5 |
| WST West Pharmaceutical Services, Inc. | $28B | 50.5 | 19.1 | 19.0 | 17.7 | 12.4 | 9 | BULLISH | 34.0 |
| EXEL Exelixis, Inc. | $16B | 19.8 | 44.4 | 69.0 | 33.7 | 9.2 | 8 | BULLISH | 68.8 |
| ICLR ICON Public Limited Company | $14B | 42.8 | 3.5 | 5.5 | 3.5 | 2.0 | 6 | BULLISH | 2.7 |
| PMCUF Pro Medicus Limited | $13B | 78.1 | 75.0 | 68.1 | 68.7 | 22.8 | 7 | BULLISH | -33.0 |
| AVTR Avantor, Inc. | $12B | -20.5 | -9.7 | -2.5 | 2.3 | -1.6 | 6 | BULLISH | 11.1 |
| GKOS Glaukos Corporation | $11B | -56.4 | -26.0 | -12.7 | -9.9 | 41.5 | 3 | BULLISH | 142.7 |
| HNGE Hinge Health, Inc. | $9.0B | 84.6 | 30.4 | -235.0 | 20.5 | 417.7 | 7 | BULLISH | 129.6 |
| HQY HealthEquity, Inc. | $8.6B | 36.3 | 11.4 | 9.9 | 18.7 | 7.3 | 8 | BULLISH | 4.5 |
| PACS PACS Group, Inc. | $7.5B | 28.0 | 28.1 | 6.9 | 5.3 | 15.2 | 8 | BULLISH | 277.8 |
| SSMXY Sysmex Corporation | $7.4B | 30.7 | 8.5 | 10.0 | 6.7 | 6.2 | 5 | BULLISH | 4.5 |
| DOCS Doximity, Inc. | $6.0B | 37.2 | 17.2 | 60.2 | 15.5 | 11.2 | 6 | BULLISH | -50.3 |
| WAY Waystar Holding Corp. | $5.5B | 38.9 | 3.8 | 3.8 | 12.8 | 19.2 | 7 | BULLISH | -28.1 |
| HKMPY Hikma Pharmaceuticals PLC | $4.6B | 12.7 | 15.3 | 12.1 | 12.9 | 6.1 | 7 | BULLISH | -5.2 |
| ARQT Arcutis Biotherapeutics, Inc. | $3.9B | 143.7 | 15.9 | 34.7 | 11.6 | 76.1 | 7 | BULLISH | 57.5 |
| ACHC Acadia Healthcare Company, Inc. | $2.9B | -2.4 | -44.5 | 6.1 | 1.3 | 4.3 | 4 | BULLISH | 27.8 |
| BVNRY Bavarian Nordic A/S | $2.9B | 13.0 | 12.3 | 7.1 | 36.0 | -5.8 | 7 | BULLISH | 1.9 |
| BHC Bausch Health Companies Inc. | $2.4B | -2.1 | 86.8 | 12.2 | 9.0 | 10.5 | 5 | BULLISH | 1.8 |
| MD Pediatrix Medical Group, Inc. | $2.4B | 13.7 | 20.4 | 15.9 | 8.2 | 0.5 | 7 | BULLISH | 64.0 |
| FTRE Fortrea Holdings Inc. | $2.2B | -26.2 | -15.3 | 0.6 | -1.9 | -2.1 | 6 | BULLISH | 116.2 |
| PGNY Progyny, Inc. | $2.2B | 28.5 | 16.2 | 30.2 | 8.0 | 5.5 | 7 | BULLISH | 42.2 |
| PRGO Perrigo Company plc | $2.2B | -1.3 | -49.6 | 3.1 | 7.3 | -4.2 | 4 | BULLISH | -23.7 |
| AGIO Agios Pharmaceuticals, Inc. | $2.2B | -5.4 | -34.3 | -82.5 | -225.1 | 140.6 | 4 | BULLISH | -12.2 |
| BOEUF Bonesupport Holding AB (publ) | $2.1B | 78.2 | 29.2 | 54.1 | 22.6 | 23.4 | 8 | BULLISH | 28.9 |
| HCA HCA Healthcare, Inc. | $102B | 53.8 | -124.7 | 23.3 | 8.4 | 7.3 | 6 | BULLISH | 0.8 |
| IDXX IDEXX Laboratories, Inc. | $44B | 39.6 | 74.2 | 46.5 | 27.8 | 12.8 | 9 | BULLISH | -12.4 |
| GEHC GE HealthCare Technologies Inc. | $32B | 20.5 | 15.4 | 10.6 | 10.8 | 1.4 | 5 | BULLISH | -9.0 |
| CLPBY Coloplast A/S | $17B | 38.9 | 18.5 | 70.9 | 19.9 | -2.9 | 5 | BULLISH | -23.4 |
| ASND Ascendis Pharma A/S | $15B | 18.2 | 121.1 | 76.2 | 61.0 | 114.8 | 7 | BULLISH | 21.7 |
| PEN Penumbra, Inc. | $13B | 79.3 | 11.4 | 13.6 | 8.9 | 17.6 | 6 | BULLISH | 28.1 |
| SGRY Surgery Partners, Inc. | $2.1B | -33.7 | -5.2 | 5.9 | -1.8 | 4.0 | 5 | BULLISH | 2.4 |
| ABT Abbott Laboratories | $179B | 38.2 | 10.7 | 7.3 | 7.4 | 8.1 | 5 | BULLISH | -18.7 |
| ISRG Intuitive Surgical, Inc. | $160B | 53.2 | 18.0 | 22.6 | 17.1 | 20.5 | 7 | BULLISH | -18.4 |
| SYK Stryker Corporation | $118B | 31.0 | 16.5 | 11.6 | 19.4 | 8.5 | 9 | BULLISH | -21.0 |
| SNY Sanofi | $100B | 23.0 | 5.7 | 6.4 | 2.8 | 13.4 | 6 | BULLISH | -18.9 |
| CHGCF Chugai Pharmaceutical Co., Ltd. | $74B | 23.3 | 23.7 | 45.1 | 34.1 | 12.6 | 6 | BULLISH | -0.7 |
| BSX Boston Scientific Corporation | $66B | 18.1 | 15.5 | 11.6 | 16.7 | 13.5 | 8 | BULLISH | -55.4 |
| UTHR United Therapeutics Corporation | $25B | 19.5 | 19.3 | 31.3 | 42.5 | 2.5 | 6 | BULLISH | 41.2 |
| PODD Insulet Corp. | $10B | 27.9 | 26.0 | 21.3 | 11.8 | 29.4 | 9 | BULLISH | -53.3 |
| BLCO Bausch + Lomb Corporation | $6.2B | -36.9 | -2.7 | 2.8 | -1.0 | 8.8 | 5 | BULLISH | 13.5 |
| IRTC iRhythm Technologies, Inc. | $4.0B | -287.0 | -9.6 | -3.4 | -0.2 | 25.6 | 6 | BULLISH | -31.5 |
| LEGN Legend Biotech Corporation | $3.6B | -42.9 | -8.1 | -8.2 | 8.6 | 59.5 | 4 | BULLISH | -32.3 |
| WILYY Demant A/S | $12B | 46.8 | 15.9 | 10.9 | 9.1 | 10.6 | 5 | BULLISH | 47.3 |
| HLN Haleon plc | $45B | 20.7 | 10.1 | 8.4 | 13.6 | 1.3 | 8 | BULLISH | 8.9 |
| ZTS Zoetis Inc. | $33B | 12.9 | 64.4 | 26.3 | 28.0 | 1.4 | 6 | BULLISH | -46.2 |
| PHG Koninklijke Philips N.V. | $26B | 20.3 | 10.2 | 7.6 | 8.8 | -1.1 | 6 | BULLISH | -8.4 |
| SNN Smith & Nephew plc | $13B | 19.7 | 11.8 | 9.9 | 9.8 | 5.3 | 7 | BULLISH | -15.5 |
| COO The Cooper Companies, Inc. | $12B | 20.4 | 6.8 | 6.3 | 40.6 | 4.7 | 6 | BULLISH | -18.5 |
| VRDN Viridian Therapeutics, Inc. | $2.5B | -6.7 | -65.7 | 418.2 | -44760.2 | 23220.3 | 4 | BULLISH | 8.7 |
| ESLOF EssilorLuxottica S.A. | $94B | 33.7 | 6.5 | 5.2 | 10.6 | 7.4 | 6 | BULLISH | -44.5 |
| SOAGY Sartorius AG ADR | $92B | 92.0 | 7.7 | 6.6 | 7.1 | 4.3 | 7 | BULLISH | 16.0 |
| EW Edwards Lifesciences Corporation | $51B | 52.1 | 9.5 | 17.9 | 13.9 | 14.6 | 6 | BULLISH | 19.3 |
| BIIB Biogen Inc. | $37B | 44.4 | 4.6 | 4.8 | 3.6 | -0.5 | 3 | BULLISH | 68.6 |
| TRUMY Terumo Corporation | $22B | 21.5 | 11.0 | 9.6 | 22.6 | 15.6 | 5 | BULLISH | -8.6 |
| ALGN Align Technology, Inc. | $11B | 26.4 | 10.2 | 12.3 | 10.3 | 4.4 | 7 | BULLISH | 12.4 |
| HTFL Heartflow, Inc. Common Stock | $4.9B | -41.1 | -42.3 | -39.8 | -24.6 | — | 2 | BULLISH | 52.7 |
| DSRLF DiaSorin S.p.A. | $4.4B | 25.1 | 14.2 | 8.9 | 14.0 | 46.3 | 5 | BULLISH | -2.4 |
| VCYT Veracyte, Inc. | $3.9B | 35.8 | 8.8 | 10.7 | 17.0 | 17.3 | 8 | BULLISH | 36.9 |
| PLSE Pulse Biosciences, Inc. | $3.8B | -44.9 | -78.5 | -1410.2 | -5681.3 | — | 3 | BULLISH | 194.2 |
| CZMWY Carl Zeiss Meditec AG | $3.5B | 21.1 | 5.6 | 4.8 | 9.8 | 22.1 | 7 | BULLISH | -26.2 |
| AVAH Aveanna Healthcare Holdings Inc. | $2.9B | 9.6 | 199.1 | 30.4 | 6.0 | 20.3 | 6 | BULLISH | 34.7 |
| SZUKF Suzuken Co., Ltd. | $2.4B | 10.9 | 9.3 | 8.6 | 0.5 | 5.0 | 4 | BULLISH | 18.9 |
| AUPH Aurinia Pharmaceuticals Inc. | $2.2B | 7.3 | 66.1 | 127.2 | 45.0 | 19.8 | 7 | BULLISH | 45.1 |
| BHVN Biohaven Ltd. | $2.1B | -3.3 | -799.5 | -1083.0 | — | — | 3 | BULLISH | -7.9 |
| NTRA Natera, Inc. | $58B | -303.0 | -12.5 | -23.6 | -8.9 | 37.8 | 6 | BULLISH | 113.4 |
| MKGAF Merck KGaA | $70B | 26.5 | 8.1 | 8.1 | 9.0 | -0.4 | 7 | BULLISH | 19.4 |
| COR Cencora, Inc. | $63B | 24.2 | 104.3 | 26.5 | 0.9 | 5.1 | 7 | BULLISH | -2.0 |
| IQV IQVIA Holdings Inc. | $46B | 32.9 | 21.7 | 33.3 | 7.9 | 8.8 | 9 | BULLISH | 23.1 |
| WAT Waters Corporation | $45B | 116.7 | 1.9 | 1.5 | -8.3 | 52.5 | 5 | BULLISH | 30.3 |
| GNMSF Genmab A/S | $28B | 34.9 | 3.9 | 11.9 | 26.2 | -82.1 | 4 | BULLISH | 47.7 |
| SONVF Sonova Holding AG | $20B | 38.9 | 20.4 | 17.2 | 19.7 | -7.1 | 6 | BULLISH | 22.9 |
| BAX Baxter International Inc. | $13B | -12.2 | -15.7 | -1.6 | 4.3 | 5.4 | 3 | BULLISH | 8.4 |
| GNGBY Getinge AB (publ) | $7.3B | 25.9 | 9.1 | 8.1 | 8.5 | -3.9 | 7 | BULLISH | 13.6 |
| HLUBF H. Lundbeck A/S | $7.3B | 13.4 | 15.2 | 12.6 | 17.6 | 10.1 | 7 | BULLISH | 22.5 |
| CNVVY ConvaTec Group Plc | $6.3B | 50.6 | 7.6 | 10.2 | 4.4 | 5.5 | 5 | BULLISH | -2.0 |
| MAHLY MediPal Holdings Corporation | $4.1B | 15.1 | 7.5 | 8.7 | 1.4 | 5.9 | 7 | BULLISH | 23.9 |
| IRON Disc Medicine, Inc. | $2.9B | -12.1 | -39.1 | 1672.3 | — | — | 1 | BULLISH | -6.7 |
| NRIX Nurix Therapeutics, Inc. | $2.8B | 10.6 | 44.0 | -1896.6 | 81.7 | 738.8 | 8 | BULLISH | 140.8 |
| ZYME Zymeworks Inc. | $2.0B | -14.3 | -72.3 | -156.9 | -980.8 | -69.8 | 2 | BULLISH | 62.6 |
| XNCR Xencor, Inc. | $1.9B | -13.7 | -29.1 | -152.4 | -42.4 | -36.1 | 2 | BULLISH | 127.0 |
| KLRA Kailera Therapeutics, Inc. | $1.7B | — | — | — | — | — | — | BULLISH | — |
| TRAX First Tracks Biotherapeutics Inc | $1.6B | — | — | — | — | — | — | BULLISH | — |
| UCBJY UCB S.A. | $58B | 23.3 | 20.7 | 16.4 | 26.0 | 25.3 | 6 | BULLISH | 5.8 |
| ALC Alcon Inc. | $34B | 53.4 | 2.9 | 3.6 | 0.0 | 7.8 | 6 | BULLISH | -8.8 |
| STE STERIS plc | $23B | 27.9 | 11.4 | 9.7 | 13.4 | 8.4 | 8 | BULLISH | -4.9 |
| LVZPF Livzon Pharmaceutical Group Inc. | $6.1B | 16.0 | 11.5 | 16.4 | 15.3 | -14.4 | 4 | BULLISH | 0.0 |
| ORKA Oruka Therapeutics, Inc. | $5.3B | -38.6 | -18.2 | -50.3 | — | — | 4 | BULLISH | 251.6 |
| GSK GSK plc | $102B | 16.0 | 25.5 | 18.8 | 5.2 | 5.0 | 7 | BULLISH | 18.9 |
| SEMHF Siemens Healthineers AG | $53B | 21.1 | 12.1 | 8.4 | 11.6 | 10.0 | 9 | BULLISH | -17.9 |
| DGX Quest Diagnostics Incorporated | $27B | 23.7 | 15.2 | 10.2 | 10.1 | 9.1 | 8 | BULLISH | 33.1 |
| SAUHY Straumann Holding AG | $19B | 41.9 | 17.3 | 21.7 | 18.1 | 3.0 | 6 | BULLISH | 4.9 |
| NBIX Neurocrine Biosciences, Inc. | $15B | 20.6 | 22.1 | 16.0 | 15.1 | 34.4 | 6 | BULLISH | 1.4 |
| GMED Globus Medical, Inc. | $11B | 20.4 | 11.8 | 12.3 | 19.2 | 19.7 | 8 | BULLISH | 29.8 |
| KYMR Kymera Therapeutics, Inc. | $9.1B | -36.7 | -24.2 | -30.7 | -94.2 | 134.8 | 6 | BULLISH | 100.8 |
| OPHLY Ono Pharmaceutical Co., Ltd. | $7.4B | 15.2 | 9.5 | 11.3 | 20.8 | 3.3 | 9 | BULLISH | 29.5 |
| ERAS Erasca, Inc. | $5.0B | -15.8 | -78.2 | -87.5 | — | — | 2 | BULLISH | 539.5 |
| LIVN LivaNova PLC | $4.4B | 23.3 | 15.4 | 30.2 | 27.8 | 12.4 | 8 | BULLISH | 46.4 |
| SNPHY Santen Pharmaceutical Co., Ltd. | $3.6B | 14.7 | 13.6 | 14.9 | 10.4 | 0.9 | 8 | BULLISH | 14.7 |
| CSLLY CSL Limited | $134B | -26.1 | -15.2 | 13.1 | -40.2 | 1.7 | 4 | BULLISH | 1.4 |
| RVTY Revvity, Inc. | $18B | 76.9 | 3.2 | 3.5 | 7.1 | 5.5 | 6 | BULLISH | 63.7 |
| TECH Bio-Techne Corporation | $11B | 62.1 | 9.0 | 8.9 | 17.0 | -0.4 | 7 | BULLISH | 10.3 |
| MOH Molina Healthcare, Inc. | $11B | -323.5 | -1.2 | -44.2 | 0.4 | -2.1 | 5 | BULLISH | 22.1 |
| MTHRY M3, Inc. | $8.2B | 27.5 | 12.1 | 16.9 | 10.1 | 17.7 | 7 | BULLISH | -17.1 |
| HAE Haemonetics Corporation | $5.4B | 58.5 | 11.2 | 10.1 | 9.7 | 0.4 | 8 | BULLISH | 134.1 |
| CDNA CareDx, Inc | $3.6B | 32.8 | 29.5 | -2.5 | 83.8 | 34.4 | 8 | BULLISH | 371.1 |
| ONTTF Oxford Nanopore Technologies plc | $2.7B | -18.0 | -25.6 | -36.2 | -41.1 | 14.4 | 4 | BULLISH | 41.7 |
| ESAIY Eisai Co., Ltd. | $9.2B | 34.0 | 3.8 | 3.3 | 7.8 | 248.0 | 6 | BULLISH | 9.7 |
| ATR AptarGroup, Inc. | $8.1B | 22.6 | 13.6 | 10.1 | 8.5 | 8.9 | 6 | BULLISH | -1.8 |
| AKBLF ALK-Abelló A/S | $7.4B | 39.9 | 21.2 | 23.9 | 18.9 | 16.4 | 8 | BULLISH | 12.8 |
| OPCH Option Care Health, Inc. | $4.7B | 23.5 | 16.0 | 10.6 | 3.7 | 5.9 | 5 | BULLISH | 12.1 |
| AMBBY Ambu A/S | $3.2B | 41.6 | 8.5 | 9.0 | 9.5 | -411.9 | 6 | BULLISH | -28.5 |
| PRVA Privia Health Group, Inc. | $2.9B | 97.1 | 0.0 | 0.0 | 1.4 | 24.1 | 1 | BULLISH | -16.0 |
| ADMA ADMA Biologics, Inc. | $2.4B | 15.4 | 41.9 | 35.5 | 30.4 | 8.0 | 5 | BULLISH | -26.4 |
| DRWKF Drägerwerk AG & Co. KGaA | $2.3B | 11.2 | 11.0 | 9.8 | 3.5 | 6.5 | 9 | BULLISH | 36.8 |
| IPSEY Ipsen S.A. | $58B | 24.6 | 11.5 | 16.3 | 18.2 | 8.0 | 6 | BULLISH | 22.7 |
| BRVE Braveheart Bio, Inc. | $1.5B | — | — | — | — | — | — | BULLISH | — |
| GILD Gilead Sciences, Inc. | $193B | -60.9 | -20.6 | -3.4 | -134.5 | 5.5 | 5 | BULLISH | 32.4 |
| DSNKY Daiichi Sankyo Company, Limited | $33B | 19.6 | 15.1 | 12.5 | 11.9 | 17.4 | 5 | BULLISH | -37.5 |
| ROIV Roivant Sciences Ltd. | $26B | -95.9 | -6.2 | -217.5 | -13164.4 | -67.6 | 1 | BULLISH | 100.5 |
| VTRS Viatris Inc. | $21B | -52.2 | -2.8 | -0.3 | -3.2 | 4.4 | 7 | BULLISH | 83.0 |
| BMXXY bioMérieux S.A. | $12B | 22.8 | 11.2 | 8.9 | 11.5 | -3.5 | 7 | BULLISH | -28.0 |
| DVA DaVita Inc. | $12B | 15.6 | -149.4 | 17.9 | 7.5 | 6.4 | 8 | BULLISH | 40.7 |
| UHS Universal Health Services, Inc. | $11B | 7.1 | 21.0 | 12.5 | 7.7 | 10.0 | 8 | BULLISH | -15.7 |
| RDY Dr. Reddy's Laboratories Limited | $11B | 39.0 | 7.5 | 6.0 | 10.7 | -3.1 | 4 | BULLISH | -5.7 |
| SEPN Septerna Inc | $1.9B | -81.5 | -6.3 | -93.1 | -48.7 | 17878.5 | 5 | BULLISH | 103.7 |
| MAZE Maze Therapeutics, Inc. | $1.7B | -11.4 | -37.3 | -112.3 | — | — | 3 | BULLISH | 4.3 |
| COAG Hemab Therapeutics Holdings, Inc. Common Stock | $1.6B | — | — | — | — | — | — | BULLISH | — |
| HUM Humana Inc. | $51B | 38.9 | 6.8 | 17.2 | 1.7 | 18.3 | 4 | BULLISH | 42.7 |
| TCHBF Tecan Group AG | $3.5B | -26.5 | -9.7 | 2.8 | 2.9 | -4.2 | 6 | BULLISH | 45.2 |
| RCDTF Recordati Industria Chimica e Farmaceutica S.p.A. | $12B | 21.7 | 24.9 | 15.4 | 16.7 | 9.2 | 7 | BULLISH | -9.2 |
| GRAL GRAIL Inc. | $5.9B | -15.7 | -16.1 | -24.9 | -246.7 | 23.1 | 5 | BULLISH | 68.5 |
| EKTAY Elekta AB (publ) | $2.2B | -60.9 | -4.4 | -49.1 | 7.5 | -7.8 | 4 | BULLISH | 9.3 |
| FSNUY Fresenius SE & Co. KGaA | $117B | 16.8 | 8.1 | 5.6 | 6.4 | 5.9 | 7 | BULLISH | -20.4 |
| ENSG The Ensign Group, Inc. | $10B | 25.8 | 17.0 | 8.1 | 6.9 | 18.9 | 7 | BULLISH | -8.9 |
| BLLN BillionToOne, Inc. | $5.1B | 166.9 | 6.0 | 25.2 | 7.4 | — | 4 | BULLISH | — |
| RARE Ultragenyx Pharmaceutical Inc. | $1.5B | -2.9 | 839.4 | -67.5 | -43.0 | 17.5 | 2 | BULLISH | -50.0 |
| THC Tenet Healthcare Corporation | $22B | 10.0 | 53.3 | 19.1 | 14.7 | 5.4 | 7 | BULLISH | 24.5 |
| SYRE Spyre Therapeutics, Inc. | $8.3B | -50.4 | -23.0 | 359.8 | — | — | 3 | BULLISH | 323.8 |
| ERFSF Eurofins Scientific SE | $17B | 28.5 | 12.8 | 4.6 | 8.2 | 3.3 | 6 | BULLISH | 25.6 |
| FSPKF Fisher & Paykel Healthcare Corporation Limited | $16B | 60.2 | 23.3 | 27.3 | 20.6 | 5.0 | 6 | BULLISH | 34.9 |
| ICUI ICU Medical, Inc. | $4.2B | 136.5 | 1.4 | 2.7 | 3.5 | -9.0 | 6 | BULLISH | 32.2 |
| ADUS Addus HomeCare Corporation | $2.3B | 21.3 | 9.7 | 9.6 | 7.3 | 15.9 | 6 | BULLISH | -0.3 |
| IMCR Immunocore Holdings plc | $1.6B | -176.2 | -2.3 | -472.0 | -0.7 | 13.4 | 4 | BULLISH | -3.4 |
| EHC Encompass Health Corporation | $12B | 19.5 | 25.5 | 16.7 | 9.6 | 9.5 | 9 | BULLISH | -3.7 |
| LQDA Liquidia Corporation | $3.8B | 29.0 | 131.8 | 391.9 | 43.5 | 2233.6 | 6 | BULLISH | 103.0 |
| XERS Xeris Biopharma Holdings, Inc. | $1.9B | -107.0 | 118.2 | 18.3 | -33.8 | 36.3 | 6 | BULLISH | 13.5 |
| NBTX Nanobiotix S.A. | $1.5B | -27.5 | 104.2 | 62.0 | -626.0 | 49.1 | 4 | BULLISH | 79.8 |
| VRTX Vertex Pharmaceuticals Incorporated | $133B | 29.9 | 23.5 | 28.3 | 33.0 | 10.6 | 6 | BULLISH | 23.6 |
| SGIOY Shionogi & Co., Ltd. | $16B | 9.8 | 13.6 | 9.9 | 50.6 | 10.3 | 5 | BULLISH | 20.6 |
| RGEN Repligen Corporation | $11B | -831.3 | -0.6 | -1.4 | -18.4 | 13.8 | 4 | BULLISH | 5.7 |
| CHEOY Cochlear Limited | $6.7B | 62.1 | 7.8 | 11.6 | -1.2 | -1.2 | 6 | BULLISH | -48.2 |
| CHE Chemed Corporation | $6.7B | 25.4 | 27.1 | 23.2 | 10.1 | 3.3 | 6 | BULLISH | 16.6 |
| LGND Ligand Pharmaceuticals Incorporated | $6.0B | 31.2 | 22.0 | 11.3 | 76.2 | 54.9 | 5 | BULLISH | 66.7 |
| APNHY Aspen Pharmacare Holdings Limited | $4.2B | 26.9 | 3.2 | 5.3 | 6.6 | -20.1 | 7 | BULLISH | 69.4 |
| VIR Vir Biotechnology, Inc. | $1.8B | -6.2 | -26.1 | -38.8 | 33.5 | 1495.9 | 5 | BULLISH | 93.5 |
| ALPMF Astellas Pharma Inc. | $30B | 12.4 | 21.4 | 16.9 | 22.1 | 17.3 | 7 | BULLISH | 60.4 |
| HCM HUTCHMED (China) Limited | $2.6B | 149.4 | 46.6 | 11.0 | 5.7 | -11.8 | 6 | BULLISH | -6.5 |
| IOVA Iovance Biotherapeutics, Inc. | $6.4B | -20.1 | -40.4 | -49.1 | -47.6 | 34.5 | 6 | BULLISH | 548.0 |
| ILMN Illumina, Inc. | $41B | 51.6 | 32.4 | 18.2 | 17.9 | 4.9 | 7 | LEAN BULL | 179.2 |
| BBIO BridgeBio Pharma, Inc. | $13B | -19.3 | 32.4 | 57.9 | -62.5 | 202.4 | 4 | LEAN BULL | 27.9 |
| SHC Sotera Health Company | $5.2B | 32.2 | 27.8 | 10.6 | 16.7 | 8.1 | 7 | LEAN BULL | 9.7 |
| TGTX TG Therapeutics, Inc. | $8.3B | 18.5 | 100.3 | 73.5 | 3.2 | 76.1 | 6 | LEAN BULL | 69.3 |
| SHTDF Sinopharm Group Co. Ltd. | $6.3B | 6.2 | 8.4 | 8.1 | 1.2 | -2.2 | 5 | LEAN BULL | -15.2 |
| MRVI Maravai LifeSciences Holdings, Inc. | $2.1B | -15.3 | -32.9 | 24.4 | -24.1 | -3.3 | 5 | LEAN BULL | 142.2 |
| A Agilent Technologies, Inc. | $49B | 35.1 | 21.0 | 14.9 | 19.3 | 8.6 | 7 | LEAN BULL | 19.9 |
| SDGCF Sundrug Co.,Ltd. | $3.3B | 13.5 | 11.4 | 10.6 | 3.7 | 4.9 | 6 | LEAN BULL | 0.0 |
| ARHCF Alfresa Holdings Corporation | $2.5B | 11.4 | 5.7 | 7.8 | 0.2 | 3.6 | 5 | LEAN BULL | 17.9 |
| INSP Inspire Medical Systems, Inc. | $2.1B | 15.2 | 18.0 | 19.7 | 0.2 | 4.3 | 8 | LEAN BULL | -7.9 |
| OSCR Oscar Health, Inc. | $8.0B | 18.4 | 34.3 | -9.6 | 7.4 | 42.8 | 7 | LEAN BULL | 62.6 |
| HOCPY HOYA Corporation | $56B | 33.4 | 27.3 | 46.1 | 25.7 | 14.2 | 6 | LEAN BULL | 12.2 |
| BIO Bio-Rad Laboratories, Inc. | $9.9B | 45.6 | 3.1 | 2.2 | 57.1 | 1.4 | 7 | LEAN BULL | 12.1 |
| KOD Kodiak Sciences Inc. | $5.5B | -21.7 | -368.4 | -630.1 | — | — | 1 | LEAN BULL | 388.6 |
| NVST Envista Holdings Corp | $3.8B | 40.2 | 3.1 | 3.2 | 7.4 | 11.9 | 7 | LEAN BULL | 15.9 |
| BMY Bristol-Myers Squibb Company | $126B | 13.5 | 46.7 | 17.8 | 25.6 | 3.1 | 8 | LEAN BULL | 46.8 |
| TEVA Teva Pharmaceutical Industries Limited | $46B | 64.2 | 9.7 | 9.3 | -13.9 | 4.1 | 7 | LEAN BULL | 113.2 |
| BIOVF Swedish Orphan Biovitrum AB | $16B | 116.9 | 3.4 | 17.2 | 14.0 | 13.3 | 4 | LEAN BULL | 37.3 |
| PBH Prestige Consumer Healthcare Inc. | $2.3B | 13.2 | 9.1 | 5.5 | 11.0 | -1.4 | 4 | LEAN BULL | -23.8 |
| RXRX Recursion Pharmaceuticals, Inc. | $2.0B | -3.9 | -56.6 | -99.7 | -1708.0 | -14.9 | 4 | LEAN BULL | -33.0 |
| SKHHY Sonic Healthcare Limited | $6.5B | 15.5 | 7.3 | 6.2 | 6.2 | 52.7 | 5 | LEAN BULL | -5.9 |
| ALBHF Alibaba Health Information Technology Limited | $6.3B | 19.9 | 11.2 | 20.8 | 3.8 | -36.2 | 3 | LEAN BULL | -50.2 |
| GH Guardant Health, Inc. | $23B | -51.1 | 171.6 | -88.3 | -35.9 | 42.7 | 6 | LEAN BULL | 146.8 |
| NEOG Neogen Corporation | $2.7B | -49.3 | -2.7 | -0.2 | -5.3 | -0.3 | 7 | LEAN BULL | 101.5 |
| FMS Fresenius Medical Care AG & Co. KGaA | $12B | 12.2 | 7.3 | 6.7 | 4.5 | -0.5 | 7 | NEUTRAL | -17.4 |
| BRKR Bruker Corporation | $8.8B | -86.2 | -3.4 | 3.0 | -6.2 | 1.6 | 6 | NEUTRAL | 55.9 |
| MSMKF MatsukiyoCocokara & Co. | $5.8B | 18.0 | 11.1 | 12.6 | 5.1 | 5.7 | 8 | NEUTRAL | -16.3 |
| ZLAB Zai Lab Limited | $2.7B | -13.3 | -26.9 | -85.4 | -47.8 | 5.1 | 3 | NEUTRAL | -10.4 |
| KYKOF Kyowa Kirin Co., Ltd. | $8.1B | 15.6 | 9.3 | 14.2 | 12.8 | 7.4 | 7 | NEUTRAL | -9.5 |
| ITGR Integer Holdings Corporation | $4.3B | 34.3 | 7.5 | 5.4 | 5.1 | 2.6 | 7 | NEUTRAL | 73.8 |
| AAVXF Abivax S.A. | $12B | -17.0 | -221.8 | 440.6 | — | -133.5 | 4 | NEUTRAL | 57.0 |
| PTGX Protagonist Therapeutics, Inc. | $9.0B | 115.5 | 11.0 | 84.1 | 76.3 | 34.8 | 7 | NEUTRAL | 88.5 |
| BCHMF Bachem Holding AG | $6.8B | 41.9 | 10.6 | 8.2 | 15.4 | 4.3 | 3 | NEUTRAL | 24.7 |
| AHICF Asahi Intecc Co., Ltd. | $5.7B | 30.5 | 20.0 | 27.8 | 14.6 | 21.6 | 9 | NEUTRAL | 32.6 |
| BUHPF Bumrungrad Hospital Public Company Limited | $4.8B | 21.0 | 27.3 | 37.3 | 30.3 | 1.6 | 5 | NEUTRAL | 23.7 |
| ANSLY Ansell Limited | $4.7B | 22.3 | 10.6 | 9.5 | 10.8 | 7.1 | 8 | NEUTRAL | 43.8 |
| CSMYF COSMOS Pharmaceutical Corporation | $3.2B | 15.6 | 11.7 | 9.8 | 2.9 | 9.5 | 6 | NEUTRAL | -13.4 |
| JDHIY JD Health International Inc. | $16B | 16.4 | 10.3 | 31.0 | 8.4 | 19.6 | 6 | NEUTRAL | -43.9 |
| CHJTF CSPC Pharmaceutical Group Limited | $14B | 10.3 | 20.7 | 36.7 | 32.8 | 88.1 | 6 | NEUTRAL | 13.3 |
| LYCA Lycia Therapeutics Inc. | $1.6B | — | — | — | — | — | — | N/A | — |
| TSUSF Tsuruha Holdings Inc. | $4.2B | 17.4 | 6.2 | 12.0 | 2.8 | 16.1 | 5 | NEUTRAL | 0.0 |
| NONOF Novo Nordisk A/S | $172B | 9.9 | 59.8 | 35.2 | 26.7 | 5.6 | 5 | NEUTRAL | -28.1 |
| IHHHF IHH Healthcare Berhad | $15B | 30.9 | 7.3 | 6.1 | 8.1 | 7.1 | 5 | NEUTRAL | 43.7 |
| DNPUF Sumitomo Pharma Co., Ltd. | $6.4B | 6.9 | 39.1 | 10.3 | 13.1 | 14.5 | 6 | NEUTRAL | 5.6 |
| SGFEF Siegfried Holding AG | $3.9B | 19.2 | 17.0 | 9.4 | 10.8 | 3.4 | 4 | NEUTRAL | -15.8 |
| PHMMF Pharma Mar, S.A. | $1.6B | 21.2 | 24.9 | 35.9 | -2.0 | 15.5 | 7 | NEUTRAL | 1.7 |
| AXGN AxoGen, Inc. | $2.2B | -56.1 | -18.2 | -5.6 | -2.2 | 23.6 | 4 | NEUTRAL | 106.2 |
| ANAB AnaptysBio, Inc. | $1.5B | 7.3 | -1146.3 | 466.0 | 668.9 | 92.9 | 5 | NEUTRAL | 112.3 |
| BTSG BrightSpring Health Services, Inc. Common Stock | $12B | 40.8 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | LEAN BEAR | 74.0 |
| GEDSF Gedeon Richter PLC | $4.5B | 10.7 | 16.4 | 22.0 | 29.6 | 4.8 | 7 | LEAN BEAR | 0.0 |
| GLPGF Lakefront Biotherapeutics | $2.1B | 3.8 | 20.2 | 39.4 | 17.4 | 259.3 | 5 | LEAN BEAR | -4.5 |
| MRNA Moderna, Inc. | $80B | -25.8 | -39.0 | -90.1 | -539.3 | -27.2 | 2 | LEAN BEAR | 724.0 |
| RDNT RadNet, Inc. | $5.5B | -277.5 | -2.1 | 1.8 | 1.2 | 18.9 | 5 | LEAN BEAR | -11.8 |
| COGT Cogent Biosciences, Inc. | $5.4B | -13.9 | -109.7 | 1964.0 | — | — | 3 | LEAN BEAR | 111.6 |
| STVN Stevanato Group S.p.A. | $5.3B | 36.1 | 9.1 | 7.2 | 7.6 | 6.7 | 6 | LEAN BEAR | -24.8 |
| DFTX Definium Therapeutics, Inc. | $4.8B | -10.8 | -25.7 | 82.4 | — | — | 2 | LEAN BEAR | — |
| INVA Innoviva, Inc. | $1.5B | 4.3 | 36.7 | 15.0 | -69.8 | 19.8 | 7 | LEAN BEAR | 18.2 |
| SUVPF Sartorius AG | $19B | 92.0 | 7.7 | 6.7 | 7.1 | 3.6 | 7 | LEAN BEAR | -0.5 |
| RLAY Relay Therapeutics, Inc. | $4.0B | -12.0 | -36.8 | -2519.7 | -23916.3 | 23.9 | 4 | LEAN BEAR | 174.6 |
| NURPF Neuren Pharmaceuticals Limited | $1.8B | 118.1 | 6.2 | 22.4 | 14.6 | -68.5 | 5 | LEAN BEAR | 20.8 |
| ALMR Alamar Biosciences, Inc. | $2.1B | — | — | — | — | — | — | LEAN BEAR | — |
| HNGZY Hangzhou Tigermed Consulting Co., Ltd | $6.9B | 597.8 | 0.5 | 1.6 | -24.2 | 12.0 | 6 | LEAN BEAR | 11.2 |
| SHJBF Shanghai Junshi Biosciences Co., Ltd. | $4.8B | -69.3 | -7.1 | -6.3 | 4.4 | 29.7 | 5 | LEAN BEAR | -20.8 |
| MCVEF Medicover AB (publ) | $4.1B | 44.6 | 16.9 | 6.8 | 3.8 | 9.4 | 7 | LEAN BEAR | 0.0 |
| CLDX Celldex Therapeutics, Inc. | $2.3B | -6.9 | -43.9 | -13685.9 | -334104.5 | -98.1 | 1 | LEAN BEAR | 12.8 |
| ZBIO Zenas BioPharma, Inc. | $1.8B | -2.9 | -199.0 | 5842.1 | -11145.6 | -93.3 | 2 | LEAN BEAR | 14.2 |
| PTKFF PT Kalbe Farma Tbk. | $2.0B | 8.9 | 15.4 | 17.6 | 9.1 | 13.2 | 5 | LEAN BEAR | -18.5 |
| RSMDF ResMed Inc. | $36B | 24.1 | 24.3 | 25.3 | 26.2 | 9.9 | 7 | LEAN BEAR | -15.5 |
| OGN Organon & Co. | $3.6B | 17.4 | 24.0 | 6.0 | 6.9 | -2.5 | 5 | LEAN BEAR | 50.4 |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | $12B | 40.8 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | LEAN BEAR | 68.8 |
| SRRK Scholar Rock Holding Corporation | $5.0B | -12.8 | -167.8 | 931.3 | — | — | 2 | LEAN BEAR | 43.2 |
| ELVN Enliven Therapeutics, Inc. | $3.0B | -26.5 | -15.3 | -6535.0 | — | — | 3 | LEAN BEAR | 112.0 |
| UFPT UFP Technologies, Inc. | $2.3B | 31.4 | 17.1 | 13.3 | 12.0 | 7.3 | 7 | LEAN BEAR | 46.7 |
| STOK Stoke Therapeutics, Inc. | $1.6B | -7.8 | -61.1 | -318.5 | -660.8 | -86.2 | 2 | LEAN BEAR | -19.1 |
| GALNF Galenica AG | $5.0B | 27.6 | 11.2 | 6.8 | 3.1 | 6.2 | 4 | BEARISH | 32.2 |
| ELAN Elanco Animal Health Incorporated | $11B | -55.3 | -3.0 | 3.7 | 3.9 | 12.0 | 5 | BEARISH | 2.7 |
| HSIC Henry Schein, Inc. | $9.5B | 24.3 | 12.2 | 8.7 | 2.7 | 6.5 | 7 | BEARISH | 32.0 |
| INDV Indivior Pharmaceuticals Inc | $4.3B | 12.1 | -152.4 | 528.3 | 35.6 | 13.5 | 4 | BEARISH | 38.2 |
| NEO NeoGenomics, Inc. | $2.2B | -43.6 | -6.3 | -4.8 | 1.1 | 11.2 | 5 | BEARISH | 61.9 |
| ABSI Absci Corporation | $1.6B | -13.4 | -57.7 | -213.1 | -10443.4 | -62.3 | 5 | BEARISH | 147.5 |
| NTLA Intellia Therapeutics, Inc. | $1.6B | -3.6 | -55.4 | -92.1 | -1392.3 | 12.6 | 5 | BEARISH | -52.0 |
| ARGX argenx SE | $55B | 41.0 | 26.0 | 50.1 | 29.8 | 162.5 | 7 | BEARISH | 8.0 |
| WXIBF WuXi Biologics (Cayman) Inc. | $26B | 31.4 | 10.6 | 16.0 | 20.7 | 16.0 | 9 | BEARISH | 20.2 |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.2B | -29.5 | -200.0 | 144.2 | -69.2 | 53.5 | 4 | BEARISH | -16.6 |
| ACAD Acadia Pharmaceuticals Inc. | $3.4B | 9.0 | 35.7 | 63.9 | 10.2 | 11.8 | 5 | BEARISH | -8.4 |
| PANHF Ping An Healthcare and Technology Company Limited | $2.1B | 20.7 | 4.6 | 5.6 | 8.8 | 2.9 | 6 | BEARISH | -61.7 |
| PVLA Palvella Therapeutics, Inc. | $1.8B | -27.4 | -46.6 | 137.5 | — | — | 3 | BEARISH | 82.1 |
| CLOV Clover Health Investments, Corp. | $2.4B | -114.2 | -5.1 | -8.3 | 3.8 | 54.0 | 4 | BEARISH | 21.2 |
| MEOBF Mesoblast Limited | $2.0B | -29.4 | -9.9 | -14.4 | -23.4 | 613.8 | 5 | BEARISH | -20.0 |
| BAYRY Bayer AG | $48B | -26.2 | -5.5 | 6.4 | 2.0 | -1.5 | 4 | BEARISH | 59.6 |
| INCY Incyte Corporation | $23B | 14.3 | 30.7 | 82.1 | 35.0 | 26.9 | 8 | BEARISH | 27.7 |
| ADPT Adaptive Biotechnologies Corporation | $4.1B | -68.5 | -39.6 | -14.1 | -55.6 | 50.1 | 5 | BEARISH | 60.6 |
| RGC Regencell Bioscience Holdings Limited | $3.8B | -311.9 | -128.5 | 1692.4 | — | — | 3 | BEARISH | -53.1 |
| CLCGY Clicks Group Limited | $3.1B | 15.8 | 47.7 | 39.1 | 6.5 | 6.3 | 6 | BEARISH | -37.3 |
| PHVS Pharvaris N.V. | $2.2B | -10.6 | -70.7 | 860.9 | — | — | 4 | BEARISH | 39.0 |
| ALVOW Alvotech | $3.9B | -8.1 | 98.5 | 3.3 | -63.2 | -12.2 | 0 | BEARISH | -85.2 |
| SOLV Solventum Corporation | $15B | 10.1 | 34.0 | 18.1 | 4.2 | -0.9 | 7 | BEARISH | 16.2 |
| SLS SELLAS Life Sciences Group, Inc. | $2.3B | -57.2 | -39.6 | 55646.0 | — | — | 4 | BEARISH | 511.6 |
| SRPT Sarepta Therapeutics, Inc. | $1.9B | -13.0 | -9.5 | -6.3 | -1.2 | -20.4 | 4 | BEARISH | -17.2 |
| CSPHF CStone Pharmaceuticals | $1.4B | -14.4 | -51.4 | -340.2 | -123.0 | 135.6 | 5 | BEARISH | -15.4 |
| TNGX Tango Therapeutics, Inc. | $3.9B | -27.3 | -21.3 | -253.2 | — | 121.5 | 3 | BEARISH | 205.2 |
| NHNKY Nihon Kohden Corporation | $3.1B | 19.1 | 7.8 | 7.9 | -1.6 | 2.6 | 9 | BEARISH | -28.8 |
| GRDN Guardian Pharmacy Services, Inc. | $2.5B | 37.6 | 31.7 | 33.2 | 6.2 | 10.3 | 7 | BEARISH | 38.8 |
| IMNM Immunome, Inc. | $2.1B | -7.4 | -64.0 | -2208.4 | — | -100.0 | 4 | BEARISH | 19.6 |
| ADRX ADARx Pharmaceuticals, Inc. | $1.9B | — | — | — | — | — | — | BEARISH | — |
| PCVX Vaxcyte, Inc. | $9.5B | -8.0 | -36.5 | -66.4 | — | — | 0 | BEARISH | 43.7 |
| BDULF Bangkok Dusit Medical Services Public Company Limited | $9.7B | 20.7 | 15.0 | 12.4 | 12.1 | 1.3 | 4 | BEARISH | -3.2 |
| XENE Xenon Pharmaceuticals Inc. | $3.4B | -7.6 | -43.6 | -109.7 | — | -100.0 | 3 | BEARISH | -11.7 |
| CELC Celcuity Inc. | $3.2B | -16.0 | -1433.7 | 1325.2 | — | — | 3 | BEARISH | -4.1 |
| DYN Dyne Therapeutics, Inc. | $2.9B | -5.1 | -81.6 | 240.4 | — | — | 2 | BEARISH | -1.1 |
| IVBXF Innovent Biologics, Inc. | $20B | 96.9 | 6.9 | 67.2 | 14.5 | 35.4 | 6 | BEARISH | -11.4 |
| RADLY Raia Drogasil S.A. | $7.2B | 20.7 | 19.4 | 16.9 | 3.8 | 10.9 | 7 | BEARISH | -17.4 |
| KNSA Kiniksa Pharmaceuticals International, plc | $6.0B | 63.0 | 14.0 | 51.6 | 10.4 | 58.9 | 7 | BEARISH | 129.1 |
| SHPMY Shanghai Pharmaceuticals Holding Co., Ltd | $5.1B | 12.8 | 6.2 | 6.5 | 2.9 | 4.1 | 5 | BEARISH | -13.8 |
| AAPG Ascentage Pharma Group International | $1.4B | -6.1 | -236.8 | -144.8 | -270.2 | 170.9 | 3 | BEARISH | -58.7 |
| BMRN BioMarin Pharmaceutical Inc. | $11B | 146.2 | 1.2 | 1.4 | 4.5 | 11.2 | 4 | BEARISH | 1.6 |
| OCPNF Olympus Corporation | $12B | 24.6 | 10.6 | 12.7 | 7.9 | 7.8 | 5 | BEARISH | -9.8 |
| GNNSF Genscript Biotech Corporation | $9.6B | -14.1 | -15.4 | 2.9 | -32.0 | 53.1 | 4 | BEARISH | 97.7 |
| ALNY Alnylam Pharmaceuticals, Inc. | $30B | 37.2 | 100.7 | -152.8 | 12.7 | 95.1 | 6 | BEARISH | -51.1 |
| MIRM Mirum Pharmaceuticals, Inc. | $5.2B | -5.9 | -703.0 | -27.3 | -38.1 | 44.0 | 3 | BEARISH | 22.2 |
| SUPN Supernus Pharmaceuticals, Inc. | $2.4B | -21.2 | -10.5 | -12.6 | -26.6 | 24.9 | 3 | BEARISH | -22.5 |
| MDLN Medline Inc. | $30B | 37.9 | 3.2 | 4.4 | 0.8 | — | 4 | BEARISH | — |
| TWST Twist Bioscience Corporation | $9.2B | -71.7 | -29.6 | -29.2 | -29.6 | 19.2 | 2 | BEARISH | 368.6 |
| LNTH Lantheus Holdings, Inc. | $6.5B | 23.8 | 22.2 | 17.1 | 19.3 | 2.3 | 5 | BEARISH | 78.7 |
| ABCL AbCellera Biologics Inc. | $3.8B | -23.5 | -17.3 | -36.2 | -1368.6 | 101.3 | 4 | BEARISH | 126.7 |
| NHC National HealthCare Corporation | $3.7B | 23.5 | 13.1 | 12.6 | 9.9 | 6.9 | 8 | BEARISH | 72.6 |
| CAMRF Camurus AB | $3.7B | 58.2 | 15.8 | 89.3 | 34.3 | -0.2 | 6 | BEARISH | -10.3 |
| RMYHY Ramsay Health Care Limited | $9.2B | 40.8 | 6.6 | 4.2 | 1.8 | 4.2 | 7 | BEARISH | 85.2 |
| DNTH Dianthus Therapeutics, Inc. | $4.3B | -610.5 | -4.1 | -60.1 | -6598.6 | -60.8 | 3 | BEARISH | 141.6 |
| IDRSF Idorsia Ltd | $1.4B | -3.5 | 27.1 | -344.5 | -203.1 | -8.1 | 1 | BEARISH | 19.6 |
| HYPMY Hypera S.A. | $3.8B | 7.9 | 13.2 | 12.8 | 21.0 | 31.8 | 8 | BEARISH | -2.2 |
| RCUS Arcus Biosciences, Inc. | $2.3B | -4.6 | -89.2 | 309.6 | -222.0 | -55.3 | 0 | BEARISH | 4.8 |
| PRAX Praxis Precision Medicines, Inc. | $7.1B | -20.8 | -38.9 | -51.2 | — | -100.0 | 4 | BEARISH | 53.8 |
| RVMDW Revolution Medicines, Inc. Warrant | $40B | -21.0 | -79.1 | 186.4 | — | — | 1 | BEARISH | 2251.5 |
| BEAM Beam Therapeutics Inc. | $2.5B | -30.2 | -8.1 | -184.5 | -25036.3 | 158.9 | 4 | BEARISH | -10.9 |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.2B | -26.6 | -64.8 | 65.7 | -258.2 | 12.2 | 4 | BEARISH | 55.3 |
| IMVT Immunovant, Inc. | $5.9B | -10.2 | -80.1 | 707.5 | -2159.6 | — | 2 | BEARISH | 52.5 |
| TRVI Trevi Therapeutics, Inc. | $1.8B | -39.6 | -19.7 | -1451.7 | — | — | 3 | BEARISH | 27.0 |
| QURE uniQure N.V. | $1.6B | -5.9 | -157.6 | 37.9 | -1387.8 | 30.2 | 4 | BEARISH | -60.2 |
| DNLI Denali Therapeutics Inc. | $2.9B | -6.7 | -54.9 | -281.7 | -3539.2 | — | 3 | BEARISH | 20.4 |
| WUXAY WuXi AppTec Co., Ltd. | $68B | 15.4 | 30.2 | 35.4 | 39.1 | 25.0 | 8 | BEARISH | 66.6 |
| TEM Tempus AI, Inc. | $12B | -50.6 | -67.4 | -19.8 | 1.5 | 50.4 | 4 | BEARISH | -19.1 |
| TXG 10x Genomics, Inc. | $9.3B | -132.5 | -9.4 | -19.8 | -11.9 | -4.3 | 5 | BEARISH | 466.6 |
| BLTE Belite Bio, Inc | $5.9B | -52.9 | -20.8 | -11.5 | — | — | 3 | BEARISH | 57.0 |
| CGON CG Oncology Inc. | $5.5B | -23.5 | -26.4 | -2066.1 | -6832.8 | 1030.3 | 3 | BEARISH | 44.1 |
| RTEZ Rest Ez Inc. | $4.2B | — | — | — | — | — | — | BEARISH | 0.0 |
| AMLX Amylyx Pharmaceuticals, Inc. | $3.4B | -19.9 | -74.7 | 2020.5 | — | 100.0 | 5 | BEARISH | 99.7 |
| INCPF InnoCare Pharma Limited | $2.4B | 18.7 | 12.6 | 45.8 | 23.1 | 108.5 | 4 | BEARISH | -50.9 |
| DMPHF Dermapharm Holding SE | $2.4B | 13.9 | 25.6 | 13.0 | 8.1 | 0.5 | 5 | BEARISH | 20.6 |
| BCRX BioCryst Pharmaceuticals, Inc. | $1.9B | -5.6 | 87.8 | 62.3 | 35.9 | 68.7 | 5 | BEARISH | 12.5 |
| GENB Generate Biomedicines, Inc. | $1.6B | -7.9 | -28.2 | -175.0 | -1065.2 | — | 1 | BEARISH | — |
| CMPS COMPASS Pathways plc | $1.6B | -2.1 | -319.1 | 48.8 | — | — | 2 | BEARISH | 88.1 |
| YPHDF Ypsomed Holding AG | $5.7B | 23.8 | 31.1 | 17.4 | 22.5 | -2.3 | 8 | BEARISH | -8.1 |
| VRBCF Virbac S.A. | $3.2B | 18.8 | 13.6 | 12.7 | 11.4 | 3.9 | 5 | BEARISH | 10.8 |
| MEDGF Medacta Group S.A. | $2.7B | 33.1 | 17.1 | 9.8 | 11.4 | 8.9 | 4 | BEARISH | 63.9 |
| ORPEF Emeis | $2.3B | -4.5 | -19.0 | 3.2 | -5.4 | 40.2 | 5 | BEARISH | 0.0 |
| CYTK Cytokinetics, Incorporated | $8.5B | -8.5 | 329.8 | 811.2 | -622.8 | -17.2 | 2 | BEARISH | 6.4 |
| MMED MiniMed Group, Inc. | $5.2B | — | — | — | — | — | — | BEARISH | — |
| VERA Vera Therapeutics, Inc. | $2.0B | -5.1 | -91.8 | 2030.6 | — | — | 1 | BEARISH | 2.6 |
| RVMD Revolution Medicines, Inc. | $40B | -21.0 | -79.1 | 186.4 | — | — | 1 | BEARISH | 241.8 |
| DXCM DexCom, Inc. | $29B | 30.5 | 38.5 | 42.9 | 19.0 | 15.5 | 9 | BEARISH | 11.7 |
| BNTX BioNTech SE | $22B | -11.5 | -9.3 | -18.0 | -777.3 | -8.2 | 2 | BEARISH | -17.6 |
| CORT Corcept Therapeutics Incorporated | $9.3B | 168.0 | 8.1 | 3.1 | 16.5 | 16.0 | 6 | BEARISH | 20.8 |
| KRYS Krystal Biotech, Inc. | $9.2B | 38.6 | 20.1 | 40.4 | 45.9 | 22.6 | 7 | BEARISH | 72.2 |
| HIMS Hims & Hers Health, Inc. | $6.2B | -45.7 | -32.0 | -7.1 | -11.5 | 28.0 | 4 | BEARISH | -42.7 |
| CRSP CRISPR Therapeutics AG | $4.8B | -10.7 | -26.1 | -253.2 | -895.3 | -62.7 | 3 | BEARISH | -23.9 |
| IDYA IDEAYA Biosciences, Inc. | $3.4B | -17.4 | -16.2 | -42.9 | -1269.6 | 3244.7 | 4 | BEARISH | 14.8 |
| TARS Tarsus Pharmaceuticals, Inc. | $3.2B | -65.1 | -13.7 | 268.1 | -10.7 | 105.2 | 5 | BEARISH | 7.1 |
| TLX Telix Pharmaceuticals Limited | $3.1B | 92.5 | 8.6 | -1.0 | 8.0 | 10.5 | 4 | BEARISH | -16.5 |
| MBX MBX Biosciences, Inc. Common Stock | $2.3B | -22.1 | -33.2 | 1634.0 | — | — | 2 | BEARISH | 211.6 |
| PGEN Precigen, Inc. | $2.2B | -5.4 | -4640.4 | -30.1 | 36.5 | 1875.0 | 5 | BEARISH | 42.0 |
| JAZZ Jazz Pharmaceuticals plc | $14B | 13.6 | 22.1 | 26.4 | 16.0 | 12.6 | 8 | BEARISH | 49.3 |
| MDGL Madrigal Pharmaceuticals, Inc. | $10B | -34.1 | -53.3 | -778.9 | -15.9 | 149.0 | 2 | BEARISH | 4.5 |
| IBRX ImmunityBio, Inc. | $8.7B | -8.8 | 122.7 | 33.7 | -449.6 | 192.9 | 4 | BEARISH | 249.4 |
| TVTX Travere Therapeutics, Inc. | $4.7B | -112.6 | -151.8 | -21.0 | -20.5 | 77.1 | 6 | BEARISH | 81.3 |
| HAWPY Haw Par Corporation Limited | $3.0B | 12.3 | 5.2 | 1.6 | 93.0 | -12.8 | 4 | BEARISH | -20.4 |
| CHSYF China Medical System Holdings Limited | $2.7B | 13.6 | 8.6 | 9.0 | 21.9 | 9.2 | 4 | BEARISH | -17.8 |
| BRCTF BioArctic AB | $2.6B | 263.7 | 5.2 | 77.4 | -4.5 | -46.1 | 3 | BEARISH | -8.6 |
| HRMY Harmony Biosciences Holdings, Inc. | $2.1B | 12.0 | 20.5 | 35.7 | 28.9 | 24.3 | 5 | BEARISH | 25.4 |
| URGN UroGen Pharma Ltd. | $1.7B | -17.2 | 86.5 | 119.0 | -19.8 | 169.5 | 2 | BEARISH | 78.8 |
| NVAX Novavax, Inc. | $1.6B | -6.6 | 323.7 | 29.2 | -94.2 | -61.6 | 2 | BEARISH | 17.6 |
| NUVB Nuvation Bio Inc. | $1.6B | -10.3 | -47.8 | 70.2 | -198.3 | 1083.6 | 4 | BEARISH | -6.2 |
| INSM Insmed Incorporated | $20B | -23.0 | -87.2 | -364.8 | -3.1 | 185.8 | 5 | BEARISH | -40.5 |
| GIKLY Grifols, S.A. | $15B | 15.9 | 8.4 | 7.4 | 8.2 | -0.2 | 6 | BEARISH | -19.0 |
| IONS Ionis Pharmaceuticals, Inc. | $7.1B | -12.7 | -105.4 | -58.5 | -42.8 | -7.4 | 3 | BEARISH | -38.0 |
| REGMF RemeGen Co., Ltd. | $5.6B | 9.1 | 108.3 | 139.6 | 83.4 | 283.6 | 7 | BEARISH | -7.7 |
| PTCT PTC Therapeutics, Inc. | $5.1B | -126.1 | 20.6 | -5.4 | 23.2 | -42.8 | 2 | BEARISH | -6.5 |
| LABFF Laboratorios Farmaceuticos Rovi, S.A. | $3.4B | 17.1 | 29.3 | 19.6 | 39.1 | 3.3 | 6 | BEARISH | -25.9 |
| PBLS Parabilis Medicines, Inc. | $3.0B | — | — | — | — | — | — | BEARISH | — |
| AMFPF Amplifon S.p.A. | $3.0B | 42.8 | 5.7 | 7.2 | 6.4 | -0.2 | 5 | BEARISH | -36.0 |
| BKD Brookdale Senior Living Inc. | $2.4B | -16.5 | -362.1 | 10.3 | 3.2 | -2.3 | 6 | BEARISH | 7.7 |
| NAMS NewAmsterdam Pharma Company N.V. | $2.3B | -9.4 | -36.8 | 8216.2 | -1732.9 | -88.9 | 2 | BEARISH | -42.6 |
| SMMT Summit Therapeutics Inc. | $12B | -13.7 | -192.5 | 1714.4 | — | — | 3 | BEARISH | -20.5 |
| SBMFF Sino Biopharmaceutical Limited | $12B | 30.4 | 21.1 | 40.0 | 17.7 | 28.2 | 7 | BEARISH | -22.9 |
| AXSM Axsome Therapeutics, Inc. | $7.6B | -37.9 | -245.1 | 859.1 | -23.5 | 56.9 | 5 | BEARISH | 9.8 |
| SFOSF Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | $5.8B | 17.8 | 10.7 | 6.3 | 8.4 | 53.9 | 7 | BEARISH | -34.2 |
| TRSBF 3SBio Inc. | $4.3B | 3.4 | 37.1 | 80.3 | 25.3 | 93.8 | 7 | BEARISH | -51.7 |
| VKTX Viking Therapeutics, Inc. | $3.1B | -5.3 | -88.9 | 495.6 | — | — | 1 | BEARISH | -27.7 |
| TMDX TransMedics Group, Inc. | $2.5B | 15.8 | 36.3 | 18.7 | 7.7 | 25.8 | 3 | BEARISH | -46.6 |
| ZLDPF Zealand Pharma A/S | $2.4B | 5.8 | 16.3 | 57.2 | 87.2 | -49.2 | 3 | BEARISH | -54.1 |
| GENSF Genus plc | $1.8B | 5.4 | 45.4 | 9.0 | 80.4 | -3.8 | 5 | BEARISH | -19.4 |
| MLYS Mineralys Therapeutics, Inc. | $1.8B | -4.9 | -80.9 | 2274.6 | — | — | 2 | BEARISH | -47.0 |
| OCUL Ocular Therapeutix, Inc. | $1.4B | -4.7 | -73.0 | -31671.3 | -584.5 | -8.1 | 3 | BEARISH | -41.5 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
EWTX vs Benchmarks
ROIC
P/E Ratio
ROE
Piotroski F